Electronic Supplementary Material (ESI) for New Journal of Chemistry. This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2024

Supporting Information for Publication

Regioselective synthesis of spiro quinazolinones via sequential hydroalkoxylation and intramolecular amide-cyclization of alkynol ureas

Subhamoy Biswas, Surjya Kumar Bora, Pallav Jyoti Arandhara and Anil K. Saikia*

Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati-781039, Assam, India, Email: <u>asaikia@iitg.ac.in</u>

Table of contents:

01.	General information	S2
02.	Experimental procedure and spectral data of compounds 1c, 1g-1k,	S3-S9
	1m-1r, 1u, 1w-1y, 1aa and 1ab	
03.	Experimental procedure and spectral data of compounds 2a-2x, 2aa	S9-S19
	and 2ab	
04.	Experimental procedure for gram-scale synthesis of compound 2l	S19-S20
05.	Experimental procedure and spectral data of compound 5	S20
06.	Experimental procedure of control experiment	S21
07.	Experimental procedure and spectral data of compounds 7a and 7b	S21-S22
08.	Experimental procedure and spectral data of compounds 8a and 8b	S23-S24
09.	Experimental procedure and spectral data of compounds 9	S24
10.	References	S24
11.	¹ H NMR, ¹³ C NMR and HRMS spectra of all new compounds	S25-S176
12.	X-Ray crystallographic data and structure of compound 2a	S177-S179

Experimental section:

General information:


All the reagents were of reagent grade (AR grade) and were used as purchased without further purification. Silica gel (60-120 mesh size) was used for column chromatography. Reactions were monitored by TLC on silica gel GF254 (0.25 mm). Melting points were recorded in an open capillary tube and are uncorrected. Fourier transform-infra red (FT-IR) spectra were recorded as neat liquid or KBr pellets. NMR spectra were recorded in CDCl₃ with tetramethylsilane as the internal standard for ¹H (500 MHz and 400 MHz) or ¹³C (125 MHz and 100 MHz) NMR. Chemical shifts (δ) are reported in ppm with abbreviations, s = singlet, d = doublet, dd = doublet of doublets, dt = doublet of triplets, t = triplet of doublets, tt = triplet of triplets, q = quartet, qd = quartet of doublets, p = quintet, h = sextet, m = multiplet and spin-spin coupling constants (*J*) are given in Hz. HRMS spectra were recorded using Q-TOF mass spectrometer.

Trifluoromethanesulfonic acid (reagent grade, 100 mL bottle) was purchased from Spectrochem and used without further purification. It is highly advisable to handle trifluoromethanesulfonic acid using glass(micro) syringes and steel needles. Disposable plastic syringes and needles should be avoided, as they may dissolve/melt in the presence of TfOH. After using triflic acid, two layers of PTFE tape were applied, followed by a layer of parafilm, to seal the bottle cap, and it was stored in the freezer at -5°C.

The starting materials, 1a, 1b, 1d, 1e, 1f, 1s, 1t, 1u, 1v and 3 were synthesized according to the literature report, and the spectroscopic data of the compounds are in good agreement with the literature data.¹

General experimental procedure and characterization data of the compounds 1c, 1g-1k, 1m-1r, 1w-1y, 1aa and 1ab:


Schematic representation of starting materials 1c, 1g-1k, 1m-1r, 1w-1y, 1aa and 1ab:



To a solution of substituted 2-iodoaniline **A** (2.0 mmol, 1.0 equiv.) in DCM (5.0 mL) under N_2 atmosphere, substituted phenyl isocyanate **B** (2.2 mmol, 1.1 equiv.) was added dropwise. The reaction mixture was stirred overnight at room temperature to obtain a white precipitate, which was then filtered and washed with n-hexane to obtain a substituted 1,3-diphenyl urea **C**.

To a mixture of Pd(PPh₃)₂Cl₂ (0.04 mmol, 0.04 equiv.), CuI (0.02 mmol, 0.02 equiv.) and iodo substituted 1,3-diphenyl urea derivatives **C** (1.0 mmol, 1.0 equiv.) in dry THF (5.0 mL) under N₂ atmosphere, triethylamine (5.0 mmol, 5.0 equiv.) was added. The reaction mixture was stirred for 10 minutes at room temperature, after which substituted homo propargylic alcohol **D** (1.2 mmol, 1.2 equiv.) was added dropwise over a period of 5 minutes. The reaction mixture was stirred for 3.0 hours (monitored by TLC analysis) before filtering through a pad of celite. The solids were washed with ethyl acetate, and the combined filtrates were concentrated in a rotary evaporator. The crude product was then purified by column chromatography to provide the corresponding product **1**.


1-(4-Butyl-2-(4-hydroxybut-1-yn-1-yl)phenyl)-3-(p-tolyl)urea (1c):



White solid; R_f (Hexane:EtOAc, 3:2) 0.60; mp 137-139 °C. Yield 315 mg, 90%. ¹H NMR (400 MHz, CDCl₃) δ 8.09 (d, J = 8.2 Hz, 1H), 7.85 (s, 1H), 7.49 (s, 1H), 7.24 (d, J = 8.4 Hz, 2H), 7.05 (d, J = 10.7 Hz, 3H), 7.02 (s,

1H), 3.82 (q, J = 5.9 Hz, 2H), 3.07 (s, 1H), 2.59 (t, J = 5.7 Hz, 2H), 2.48 (t, J = 7.7 Hz, 2H), 2.26 (s, 3H), 1.57–1.49 (m, 2H), 1.32 (h, J = 7.4 Hz, 2H), 0.91 (t, J = 7.3 Hz, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 153.4, 138.6, 136.5, 136.1, 133.2, 130.1, 129.7, 129.5, 120.7, 118.4, 111.9, 94.5, 79.1, 61.5, 34.8, 33.6, 24.0, 22.3, 20.9, 14.1. IR (KBr, neat) 3321, 2955, 2926, 2859, 1666, 1589, 1529, 1509, 1414, 1310, 1292, 1250, 1207, 1042, 936, 895, 815, 736, 507 cm⁻¹. HRMS (ESI) calcd. for C₂₂H₂₇N₂O₂ (M + H)⁺ 351.2067, found 351.2070.


1-(4-Bromo-2-(4-hydroxybut-1-yn-1-yl)phenyl)-3-(p-tolyl)urea (1g):



White solid; R_f (Hexane:EtOAc, 3:2) 0.50; mp 183-185 °C. Yield 328 mg, 88%. ¹H NMR (400 MHz, CDCl₃/DMSOd₆) δ 8.37 (s, 1H), 8.27 (s, 1H), 8.24 (d, *J* = 8.9 Hz, 1H), 7.40 (d, *J* = 2.3 Hz, 1H), 7.37–7.32 (m, 3H), 7.09 (d, *J* = 8.0

Hz, 2H), 5.10 (s, 1H), 3.89 (q, J = 5.1 Hz, 2H), 2.72 (t, J = 5.7 Hz, 2H), 2.29 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃/DMSO-d₆) δ 152.6, 140.4, 136.4, 132.5, 132.2, 131.8, 129.4, 119.4, 119.2, 113.4, 113.1, 97.2, 77.4, 60.7, 24.1, 20.7. IR (KBr, neat) 3311, 1680, 1600, 1571, 1549, 1512, 1403, 1295, 1208, 1039, 811, 752, 690, 573, 508 cm⁻¹. HRMS (ESI) calcd. for C₁₈H₁₈BrN₂O₂ (M + H)⁺ 373.0546, found 373.0540.


1-(2-(4-Hydroxybut-1-yn-1-yl)-4-(trifluoromethyl)phenyl)-3-(p-tolyl)urea (1h):



White solid; R_f (Hexane:EtOAc, 3:2) 0.50; mp 156-158 °C. Yield 341 mg, 94%; ¹H NMR (400 MHz, CDCl₃) δ 8.43 (d, J = 8.6 Hz, 1H), 8.21 (s, 1H), 7.67 (s, 1H), 7.46 (d, J = 9.9Hz, 2H), 7.24 (d, J = 8.6 Hz, 2H), 7.03 (d, J = 7.9 Hz, 2H),

3.93 (t, J = 5.7 Hz, 2H), 2.88 (s, 1H), 2.67 (t, J = 5.7 Hz, 2H), 2.26 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 152.8, 143.9, 135.6, 133.4, 129.7, 126.9, 126.1 (q, J = 3.9 Hz), 124.1 (q, J = 270.5 Hz), 123.5 (q, J = 32.7 Hz), 120.1, 117.1, 111.5, 96.7, 78.0, 61.5, 24.0, 20.8. IR (KBr, neat) 3318, 2891, 1685, 1610, 1590, 1539, 1514, 1427, 1334, 1315, 1260, 1203, 1166, 1118, 1074, 1039, 897, 839, 813, 705, 643, 508 cm⁻¹. HRMS (ESI) calcd. for C₁₉H₁₈F₃N₂O₂ (M + H)⁺ 363.1315, found 363.1315.


1-(4-Acetyl-2-(4-hydroxybut-1-yn-1-yl)phenyl)-3-(p-tolyl)urea (1i):



White solid; R_f (Hexane:EtOAc, 3:2) 0.50; mp 175-177 °C. Yield 296 mg, 88%; ¹H NMR (500 MHz, CDCl₃) δ 8.40 (d, *J* = 8.7 Hz, 1H), 8.27 (s, 1H), 7.84–7.81 (m, 2H), 7.77 (s, 1H), 7.28 (d, *J* = 8.3 Hz, 2H), 7.07 (d, *J* = 8.0

Hz, 2H), 3.93 (t, J = 5.6 Hz, 2H), 3.04 (s, 1H), 2.68 (t, J = 5.7 Hz, 2H), 2.50 (s, 3H), 2.28 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 196.9, 152.5, 145.3, 135.8, 133.4, 130.4, 130.3, 130.0, 129.7, 120.2, 116.7, 111.3, 96.1, 78.4, 61.7, 26.4, 24.0, 20.9. IR (KBr, neat) 3339, 2927, 2885, 1669, 1577, 1512, 1409, 1359, 1289, 1253, 1196, 1143, 1044, 819, 729cm⁻¹; HRMS (ESI) calcd. for C₂₀H₂₁N₂O₃ (M + H)⁺ 337.1547, found 337.1547.


Methyl 3-(4-hydroxybut-1-yn-1-yl)-4-(3-(p-tolyl)ureido)benzoate (1j):



White solid; R_f (Hexane:EtOAc, 1:1) 0.50; mp 152-154 °C. Yield 300 mg, 85%; ¹H NMR (400 MHz, CDCl₃/DMSO-d₆) δ 8.56 (s, 1H), 8.51–8.46 (m, 1H), 8.42–8.36 (m, 1H), 7.95–7.91 (m, 1H), 7.89–7.84 (m,

1H), 7.37–7.31 (m, 2H), 7.08–7.02 (m, 2H), 5.26 (s, 1H), 3.89–3.82 (m, 5H), 2.73–2.66 (m, 2H), 2.28–2.23 (m, 3H). $^{13}C{^{1}H}$ NMR (125 MHz, CDCl₃/DMSO-d₆) δ 166.2, 152.2, 145.1, 136.2, 132.2, 131.6, 130.4, 129.3, 122.5, 119.1, 116.7, 111.1, 96.7, 77.7, 60.7, 51.8, 24.0, 20.6. IR (KBr, neat) 3325, 2951, 1708, 1606, 1581, 1511, 1435, 1286, 1249, 1193, 1116, 1038, 815, 764, 734, 541, 507 cm⁻¹. HRMS (ESI) calcd. for C₂₀H₂₁N₂O₄ (M + H)⁺ 353.1496, found 353.1496.


1-(2-(4-Hydroxybut-1-yn-1-yl)-3,4-dimethylphenyl)-3-(p-tolyl)urea (1k):



White solid; R_f (Hexane:EtOAc, 3:2) 0.50; mp 191-193 °C. Yield 277 mg, 86%; ¹H NMR (500 MHz, CDCl₃/DSO-d₆) δ 8.63 (s, 1H), 8.30 (s, 1H), 8.28 (s, 1H), 7.59–7.56 (m, 3H), 7.27 (d, *J* = 8.2 Hz, 2H), 5.27 (t, *J* = 6.2 Hz, 1H), 4.06

(q, J = 5.9 Hz, 2H), 2.90 (t, J = 5.8 Hz, 2H), 2.49 (s, 3H), 2.45 (s, 3H), 2.36 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃/DSO-d₆) δ 152.8, 138.7, 137.6, 136.7, 131.6, 130.9, 129.4, 129.1, 119.3, 118.9, 108.9, 94.5, 78.5, 60.7, 24.0, 20.6, 20.1, 18.7. IR (KBr, neat) 3342, 2926, 1664, 1599, 1513, 1436, 1275, 1266, 1047, 753, 724, 696, 541 cm⁻¹; HRMS (ESI) calcd. for C₂₀H₂₃N₂O₂ (M + H)⁺ 323.1754, found 323.1754.


1-(4-Butyl-2-(4-hydroxybut-1-yn-1-yl)phenyl)-3-phenylurea (1m):



White solid; R_f (Hexane:EtOAc, 3:2) 0.60; mp 135-137 °C. Yield 289 mg, 86%; ¹H NMR (400 MHz, CDCl₃) δ 8.07 (d, J = 8.3 Hz, 1H), 7.95 (s, 1H), 7.78–7.73 (m, 1H), 7.36 (d, J = 7.8 Hz, 2H), 7.21 (t, J = 7.6 Hz, 2H), 7.06 (s, 1H), 7.04 (d, J =

8.7 Hz, 1H), 6.98 (t, J = 7.4 Hz, 1H), 3.83 (q, J = 4.6 Hz, 2H), 3.31 (s, 1H), 2.61 (t, J = 5.6 Hz, 2H), 2.46 (t, J = 7.6 Hz, 2H), 1.52 (p, J = 7.3 Hz, 2H), 1.31 (h, J = 7.5 Hz, 2H), 0.91 (t, J = 7.3 Hz, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 153.3, 138.8, 138.5, 136.7, 130.0, 129.4, 129.1, 123.3, 120.0, 118.4, 112.1, 94.7, 79.2, 61.6, 34.8, 33.6, 24.0, 22.3, 14.0. IR (KBr, neat) 3324, 2926, 2856, 1690, 1588, 1550, 1526, 1498, 1442, 1303, 1257, 1214, 1036, 824, 746, 692, 505 cm⁻¹. HRMS (ESI) calcd. for C₂₁H₂₅N₂O₂ (M + H)⁺ 337.1911, found 337.1917.


1-(4-Fluoro-2-(4-hydroxybut-1-yn-1-yl)phenyl)-3-phenylurea (1n):



White solid; R_f (Hexane:EtOAc, 3:2) 0.50; mp 175-177 °C. Yield 283 mg, 95%; ¹H NMR (400 MHz, CDCl₃/DMSO-d₆) δ 8.36 (s, 1H), 8.23–8.19 (m, 2H), 7.44 (d, J = 7.8 Hz, 2H), 7.25 (d, J = 4.0 Hz, 1H), 7.22 (d, J = 8.2 Hz, 1H), 7.00-6.90 (m, 3H),

5.10–5.00 (m, 1H), 3.85 (q, J = 5.9 Hz, 2H), 2.67 (t, J = 5.6 Hz, 2H). ¹³C{¹H} NMR (125 MHz, CDCl₃/DMSO-d₆) δ 157.1 (d, J = 239.0 Hz), 152.8, 139.3, 137.6 (d, J = 2.3 Hz), 128.9, 122.6, 119.6 (d, J = 8.3 Hz), 119.0, 116.4 (d, J = 23.6 Hz), 116.0, 115.8, 96.9, 78.0, 60.8, 24.1. ¹⁹F NMR (470 MHz, CDCl₃/DMSO-d₆/C₆F₆) δ -125.0. IR (KBr, neat) 3231, 2927, 1667, 1599, 1534, 1499, 440, 1311, 1255, 1201, 1166, 0144, 940, 869, 751, 693, 510 cm⁻¹. HRMS (ESI) calcd. for C₁₇H₁₆FN₂O₂ (M + H)⁺ 299.1190, found 299.1190.


1-(2-(4-Hydroxybut-1-yn-1-yl)-5-methylphenyl)-3-phenylurea (10):



White solid; R_f (Hexane:EtOAc, 3:2) 0.50; mp 143-145 °C. Yield 265 mg, 90%; ¹H NMR (500 MHz, CDCl₃) δ 8.09 (s, 1H), 8.00 (s, 1H), 7.77 (s, 1H), 7.39 (d, J = 7.9 Hz, 2H), 7.24 (t, J = 7.8 Hz, 2H), 7.13 (d, J = 7.8 Hz, 1H), 7.00 (t, J = 7.3

Hz, 1H), 6.71 (d, J = 7.8 Hz, 1H), 3.87 (t, J = 5.5 Hz, 2H), 2.64 (t, J = 5.7 Hz, 2H), 2.31 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 153.1, 140.8, 139.8, 138.9, 129.8, 129.1, 123.3, 122.8, 119.8, 118.8, 108.9, 94.5, 79.2, 61.7, 24.1, 22.1. IR (KBr, neat) 3314, 2928, 1679, 1603, 1542, 1498, 1475, 1433, 1317, 1294, 1250, 1213, 1047, 839, 805, 745, 690, 504 cm⁻¹. HRMS (ESI) calcd. for C₁₈H₁₉N₂O₂ (M + H)⁺ 295.1441, found 295.1442.


1-(5-Chloro-2-(4-hydroxybut-1-yn-1-yl)phenyl)-3-phenylurea (1p):



White solid; R_f (Hexane:EtOAc, 3:2) 0.50; mp 150-152 °C. Yield 293 mg, 93%; ¹H NMR (400 MHz, CDCl₃) δ 8.39 (d, J = 2.1 Hz, 1H), 8.12 (s, 1H), 7.73 (s, 1H), 7.37–7.34 (m, 2H), 7.25–7.20 (m, 2H), 7.11 (d, J = 8.2 Hz, 1H), 7.01 (t, J = 7.4 Hz, 1H),

6.85 (dd, J = 8.2, 2.1 Hz, 1H), 3.94 (q, J = 5.9 Hz, 2H), 2.79 (t, J = 6.7 Hz, 1H), 2.69 (t, J = 5.6 Hz, 2H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 152.6, 142.1, 138.6, 135.2, 130.5, 129.2, 123.4, 121.8, 119.7, 117.8, 109.7, 96.1, 78.5, 61.8, 24.1. IR (KBr, neat) 3324, 2930, 1680, 1601, 1569, 1551, 1523, 1499, 1441, 1417, 1314, 1246, 1208, 1043, 809, 749, 692, 504 cm⁻¹; HRMS (ESI) calcd. for C₁₇H₁₆ClN₂O₂ (M + H)⁺ 315.0895, found 315.0896.


1-(2-(4-Hydroxybut-1-yn-1-yl)phenyl)-3-(4-methoxyphenyl)urea (1q):



White solid; R_f (Hexane:EtOAc, 1:1) 0.50; mp 154-156 °C. Yield 264 mg, 85%; ¹H NMR (500 MHz, CDCl₃/DMSO-d₆) δ 8.31 (d, J = 8.3 Hz, 1H), 8.17 (s, 1H), 8.04 (s, 1H), 7.37 (d, J = 9.0 Hz, 2H), 7.31–7.27 (m, 2H), 6.92 (td, J = 7.6, 1.2 Hz,

1H), 6.84 (d, J = 8.8 Hz, 2H), 4.53 (s, 1H), 3.88 (t, J = 5.1 Hz, 2H), 3.78 (s, 3H), 2.68 (t, J = 5.7 Hz, 2H). ¹³C{¹H} NMR (125 MHz, CDCl₃/DMSO-d₆) δ 155.8, 153.3, 141.2, 132.0, 130.2, 129.1, 121.8, 121.5, 118.0, 114.3, 111.6, 95.6, 78.8, 61.1, 55.6, 24.1. IR (KBr, neat) 3318, 2944, 1668, 1608, 1578, 1537, 1509, 1447, 1301, 1241, 1215, 1177, 1036, 830, 753, 521 cm⁻¹. HRMS (ESI) calcd. for C₁₈H₁₉N₂O₃ (M + H)⁺ 311.1390, found 311.1396.


1-(2-(4-Hydroxybut-1-yn-1-yl)phenyl)-3-(4-(trifluoromethyl)phenyl)urea (1r):



White solid; R_{*f*} (Hexane:EtOAc, 3:2) 0.50; mp 171-173 °C. Yield 293 mg, 84%; ¹H NMR (400 MHz, CDCl₃) δ 8.28 (d, *J* = 8.4 Hz, 1H), 8.22 (s, 1H), 8.05 (s, 1H), 7.50 (d, *J* = 8.6 Hz, 2H), 7.45 (d, *J* = 8.7 Hz, 2H), 7.29 (td, J = 7.9, 1.1 Hz, 1H),

7.24 (dd, J = 7.8, 1.0 Hz, 1H), 6.93 (td, J = 7.5, 1.1 Hz, 1H), 4.02 (q, J = 5.7 Hz, 2H), 2.75 (t, J = 5.6 Hz, 2H), 2.70 (t, J = 6.5 Hz, 1H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 152.4, 142.4, 140.8, 129.9, 129.5, 126.3 (q, J = 3.7 Hz), 124.5 (q, J = 32.3 Hz), 124.4 (q, J = 269.7 Hz), 122.1, 118.2, 117.8, 111.6, 95.3, 79.3, 62.1, 24.2. ¹⁹F NMR (470 MHz, CDCl₃/C₆F₆) δ -65.04. IR (KBr, neat) 3328, 2927, 2858, 1661, 1605, 1584, 1534, 1450, 1411, 1321, 1257, 1164, 1115, 1067, 842, 752, 701, 592 cm⁻¹. HRMS (ESI) calcd. for C₁₈H₁₆F₃N₂O₂ (M + H)⁺ 349.1158, found 349.1158.


1-Benzyl-3-(2-(4-hydroxyhex-1-yn-1-yl)phenyl)urea (1w):



White solid; R_f (Hexane:EtOAc, 7:3) 0.60; mp 125-127 °C. Yield 313 mg, 97%; ¹H NMR (400 MHz, CDCl₃) δ 8.26 (d, J = 8.3 Hz, 1H), 8.12 (s, 1H), 7.30–7.27 (m, 4H), 7.25–7.18 (m, 3H), 6.85 (td, J = 7.5, 1.2 Hz, 1H), 6.41 (s, 1H), 4.39 (d, J = 5.7 Hz, 2H), 3.97–3.71 (m, 2H), 2.70 (dd, J = 17.1, 4.0 Hz, 1H), 2.50 (dd, J = 17.1, 6.3 Hz, 1H), 1.64–1.51 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H).

¹³C{¹H} NMR (125 MHz, CDCl₃) δ 155.6, 141.7, 139.6, 130.0, 129.1, 128.6, 127.6, 127.1, 121.1, 117.9, 111.4, 94.9, 79.2, 72.1, 43.9, 29.2, 28.0, 10.3. IR (KBr, neat) 3325, 2965, 2930, 1669, 1545, 1450, 1305, 1245, 1217, 1100, 1025, 979, 840, 752, 697, 477cm⁻¹. HRMS (ESI) calcd. for $C_{20}H_{23}N_2O_2$ (M + H)⁺ 323.1754, found 323.1757.


1-(2-(4-Cyclohexyl-4-hydroxybut-1-yn-1-yl)phenyl)-3-(*p*-tolyl)urea (1x):



White solid; R_f (Hexane:EtOAc, 7:3) 0.60; mp 133-135 °C. Yield 301 mg, 80%; ¹H NMR (500 MHz, CDCl₃) δ 8.27 (d, J = 8.3 Hz, 1H), 8.16 (s, 1H), 7.86 (s, 1H), 7.24 (d, J = 7.9 Hz, 2H), 7.21 (d, J = 7.8 Hz, 1H), 7.17 (d, J = 8.3 Hz, 1H), 6.98 (d, J = 8.0 Hz, 2H), 6.83 (t, J = 7.5 Hz, 1H), 3.58–3.53 (m, 1H), 2.96

(d, J = 7.8 Hz, 1H), 2.62 (dd, J = 17.1, 3.6 Hz, 1H), 2.48 (dd, J = 17.1, 8.1 Hz, 1H), 2.21 (s, 3H), 1.97–1.92 (m, 1H), 1.73 (d, J = 12.5 Hz, 2H), 1.64 (t, J = 13.4 Hz, 2H), 1.48–1.41 (m, 1H), 1.27–1.08 (m, 3H), 1.04–0.95 (m, 2H). $^{13}C{^{1}H}$ NMR (125 MHz, CDCl₃) δ 153.2, 141.5, 136.4, 132.4, 129.6, 129.5, 129.1, 121.3, 119.4, 117.5, 111.6, 95.6, 79.2, 76.0, 43.2, 29.2, 29.0, 26.3, 26.0, 25.95, 25.93, 20.8. IR (KBr, neat) 3320, 3039, 2923, 2852, 161, 1603, 1578, 1534, 1512, 1448, 1406, 1309, 1293, 1247, 1204, 1106, 1031, 815, 748, 703, 507 cm⁻¹. HRMS (ESI) calcd. for C₂₄H₂₉N₂O₂ (M + H)⁺ 377.2224, found 377.2225.


1-(3-(4-Hydroxybut-1-yn-1-yl)pyridin-2-yl)-3-(p-tolyl)urea (1y):



White solid; R_f (Hexane:EtOAc, 3:2) 0.50; mp 128-130°C. Yield 266 mg, 90%. ¹H NMR (500 MHz, CDCl₃) δ 11.67 (s, 1H), 8.15 (d, J = 5.3 Hz, 1H), 7.91 (s, 1H), 7.65 (d, J = 7.6 Hz, 1H), 7.46 (d, J = 8.6 Hz, 2H), 7.14 (d, J = 8.0 Hz, 2H), 6.87 (dd,

J = 7.3, 5.1 Hz, 1H), 3.90 (t, J = 6.2 Hz, 2H), 2.92 (s, 1H), 2.78 (t, J = 6.1 Hz, 2H), 2.32 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 153.2, 152.5, 144.9, 140.6, 135.8, 133.3, 129.6, 120.5, 116.5, 107.3, 97.7, 75.6, 60.8, 24.0, 21.0. IR (KBr, neat) 3393, 2948, 2231, 1679, 1610, 1582, 1556, 1478, 1409, 1315, 1258, 1226, 1048, 814, 749, 510 cm⁻¹. HRMS (ESI) calcd. for C₁₇H₁₈N₃O₂ (M + H)⁺ 296.1394, found 296.1394.

1-(2-(5-Hydroxypent-1-yn-1-yl)phenyl)-3-(p-tolyl)urea (1aa):




White solid; R_f (Hexane:EtOAc, 1:1) 0.50; mp 146-148 °C. Yield 284 mg, 92%. ¹H NMR (500 MHz, CDCl₃) δ 8.33 (d, *J* = 8.3 Hz, 1H), 8.03 (s, 1H), 8.00 (s, 1H), 7.32 (d, *J* = 8.5 Hz, 3H), 7.28 (t, *J* = 7.9 Hz, 1H), 7.10 (d, *J* = 7.5 Hz, 2H), 6.95 (t,

J = 7.5 Hz, 1H), 3.96 (t, J = 4.8 Hz, 2H), 2.91 (s, 1H), 2.60 (t, J = 5.8 Hz, 2H), 2.32 (s, 3H), 1.91–1.86 (m, 2H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 153.4, 141.1, 136.1, 133.0, 130.9, 129.6, 129.0, 121.6, 120.3, 119.0, 111.9, 96.8, 77.2, 63.1, 30.6, 20.9, 17.4. IR (KBr, neat) 3326,

2932, 1672, 1605, 1579, 1537, 1513, 1448, 1297, 1252, 1208, 1046, 816, 752, 508 cm⁻¹. HRMS (ESI) calcd. for $C_{19}H_{21}N_2O_2$ (M + H)⁺ 309.1598, found 309.1598.

1-(4-Ethyl-2-(5-hydroxypent-1-yn-1-yl)phenyl)-3-(p-tolyl)urea (1ab):




White solid; R_f (Hexane:EtOAc, 1:1) 0.50; mp 131-133 °C. Yield 306 mg, 91%. ¹H NMR (500 MHz, CDCl₃) δ 8.14 (d, J = 8.5 Hz, 1H), 7.79 (s, 1H), 7.75 (s, 1H), 7.27 (s, 1H), 7.25 (s, 1H), 7.09 (s, 1H), 7.07–7.04 (m, 3H), 3.90 (t, J = 5.5 Hz,

2H), 2.65 (s, 1H), 2.55–2.50 (m, 4H), 2.27 (s, 3H), 1.82 (p, J = 5.9 Hz, 2H), 1.17 (t, J = 7.6 Hz, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 153.4, 138.7, 137.7, 136.2, 133.0, 130.1, 129.7, 128.7, 120.5, 118.4, 112.0, 96.2, 77.6, 63.1, 30.7, 28.1, 20.9, 17.3, 15.7. IR (KBr, neat) 3307, 2961, 1672, 1610, 1583, 1511, 1413, 1293, 1252, 1201, 1061, 894, 812, 750, 507 cm⁻¹. HRMS (ESI) calcd. for C₂₁H₂₅N₂O₂ (M + H)⁺ 337.1911, found 337.1911.

General experimental procedure and characterization data of the compounds 2a-2x, 2aa, 2ab:

To an ice-cold suspension of alkynol substituted diphenyl urea **1** (0.4 mmol, 1.0 equiv.) in DCM (4.0 mL), triflic acid (0.8 mmol, 2.0 equiv.) was added under N₂ atmosphere. The reaction was continued to stir at room temperature till all the starting material was consumed, as evident by TLC. It was then treated with saturated NaHCO₃ solution, and the organic layer was extracted with DCM (2 x 10 mL). The combined organic layers were further washed with brine, followed by drying over anhydrous Na₂SO₄. The organic phase was concentrated in a rotary evaporator to give the crude product, which was then subjected to column chromatography over silica gel to provide the final product.


(S)-3'-(p-Tolyl)-4,5-dihydro-1'H,3H-spiro[furan-2,4'-quinazolin]-2'(3'H)-one (2a):



White solid; R_f (Hexane:EtOAc, 1:1) 0.50; mp 239-241 °C. Yield 117 mg, 99%; ¹H NMR (500 MHz, CDCl₃) δ 8.57–8.39 (m, 1H), 7.28 (d, J = 7.9 Hz, 2H), 7.25–718 (m, 4H), 7.00 (t, J = 7.6 Hz, 1H), 6.71 (d, J = 7.9 Hz, 1H), 3.87 (q, J = 7.6 Hz, 1H), 3.69 (td, J = 7.9, 5.3 Hz, 1H), 2.50–2.44 (m, 1H), 2.40–2.35 (m, 4H), 1.90–

1.83 (m, 1H), 1.43–1.34 (m, 1H); ${}^{13}C{}^{1}H$ NMR (125 MHz, CDCl₃) δ 152.9, 137.8, 135.4, 134.9, 131.2, 129.6, 129.3, 125.1, 124.3, 122.2, 114.4, 97.2, 69.6, 39.2, 26.1, 21.3. IR (KBr, neat) 3202, 3060, 2922, 2855, 1668, 1600, 1502, 1404, 1271, 1189, 1025, 932, 786, 748, 661, 507 cm⁻¹; HRMS (ESI) calcd. for C₁₈H₁₉N₂O₂ (M + H)⁺ 295.1441, found 295.1441.


(S)-6'-Methyl-3'-(p-tolyl)-4,5-dihydro-1'H,3H-spiro[furan-2,4'-quinazolin]-2'(3'H)-one (2b):



White solid; R_f (Hexane:EtOAc, 1:1) 0.50; mp 241-243 °C. Yield 122 mg, 99%; ¹H NMR (400 MHz, CDCl₃) δ 8.51 (s, 1H), 7.29 (d, J = 8.0 Hz, 2H), 7.23 (d, J = 8.2 Hz, 2H), 7.07 (s, 1H), 7.02 (dd, J = 8.0, 1.9 Hz, 1H), 6.63 (d, J = 8.1 Hz, 1H), 3.89 (q, J = 7.6 Hz, 1H), 3.68 (td, J = 7.9, 5.2 Hz, 1H), 2.51–

2.44 (m, 1H), 2.41 (s, 3H), 2.40–2.34 (m, 1H), 2.31 (s, 3H), 1.91–1.83 (m, 1H), 1.41–1.34 (m, 1H); ${}^{13}C{}^{1}H{}$ NMR (125 MHz, CDCl₃) δ 152.9, 137.7, 135.5, 132.5, 131.5, 131.2, 130.0, 129.5, 125.2, 124.1, 114.3, 97.2, 69.6, 39.3, 26.1, 21.3, 21.1. IR (KBr, neat) 3197, 3058, 2916, 1663, 1605, 1501, 1438, 1375, 1268, 1041, 935, 750, 654, 578, 465 cm⁻¹; HRMS (ESI) calcd. for C₁₉H₂₁N₂O₂ (M + H)⁺ 309.1598, found 309.1598.


(S)-6'-Butyl-3'-(p-tolyl)-4,5-dihydro-1'H,3H-spiro[furan-2,4'-quinazolin]-2'(3'H)-one (2c):



White solid; R_f (Hexane:EtOAc, 3:2) 0.50; mp 184-186 °C. Yield 139 mg, 99%; ¹H NMR (400 MHz, CDCl₃) δ 8.35– 8.29 (m, 1H), 7.29 (d, J = 8.2 Hz, 2H), 7.23 (d, J = 8.1 Hz, 2H), 7.07 (s, 1H), 7.03 (dd, J = 8.2, 1.9 Hz, 1H), 6.64 (d, J = 8.0 Hz, 1H), 3.89 (q, J = 7.6 Hz, 1H), 3.69 (td, J = 7.9, 5.1


Hz, 1H), 2.57 (t, J = 7.8 Hz, 2H), 2.51–2.44 (m, 1H), 2.40 (s, 3H), 2.39–2.35 (m, 1H), 1.91– 1.83 (m, 1H), 1.61–1.53 (m, 2H), 1.42–1.31 (m, 3H), 0.93 (t, J = 7.3 Hz, 3H); ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 152.9, 137.7, 136.8, 135.6, 132.6, 131.2, 129.6, 129.3, 124.7, 124.1, 114.2, 97.3, 69.6, 39.2, 35.4, 34.0, 26.2, 22.4, 21.3, 14.1. IR (KBr, neat) 3195, 3041, 2925, 2869, 1671, 1604, 1510, 1423, 1395, 1268, 1194, 1102, 1055, 1025, 815, 736, 642, 512 cm⁻¹; HRMS (ESI) calcd. for C₂₂H₂₇N₂O₂ (M + H)⁺ 351.2067, found 351.2067.

(S)-6'-(*tert*-Butyl)-3'-(*p*-tolyl)-4,5-dihydro-1'*H*,3*H*-spiro[furan-2,4'-quinazolin]-2'(3'*H*)one (2d):



White solid; R_f (Hexane:EtOAc, 3:2) 0.50; mp 211-213 °C. Yield 135 mg, 96%; ¹H NMR (400 MHz, CDCl₃) δ 8.37 (s, 1H), 7.22–7.17 (m, 3H), 7.17–7.14 (m, 3H), 6.58 (d, J = 8.3 Hz, 1H), 3.82 (q, J = 7.6 Hz, 1H), 3.61 (td, J = 7.8, 5.2 Hz, 1H), 2.44–2.37 (m, 1H), 2.32 (s, 3H), 2.31–2.26 (m, 1H), 1.85–1.76 (m, 1H), 1.38–1.29 (m, 1H), 1.22 (s, 9H). $^{13}C{^{1}H}$ NMR (125 MHz, CDCl₃) δ 152.9, 145.0, 137.7, 135.5, 132.4, 131.2, 129.5, 126.5, 123.6, 121.3, 114.0, 97.4, 69.6, 39.3, 34.5, 31.5, 26.2, 21.3. IR (KBr, neat) 3228, 3049, 2956, 2869, 1671, 1605, 1510, 120, 1388, 1261, 1146, 1106, 1032, 954, 886, 824, 732, 644, 513 cm⁻¹; HRMS (ESI) calcd. for C₂₂H₂₇N₂O₂ (M + H)⁺ 351.2067, found 351.2078.


(S)-6'-Fluoro-3'-(*p*-tolyl)-4,5-dihydro-1'*H*,3*H*-spiro[furan-2,4'-quinazolin]-2'(3'*H*)-one (2e):



White solid; R_f (Hexane:EtOAc, 1:1) 0.50; mp 236-238 °C. Yield 122 mg, 98%; ¹H NMR (500 MHz, CDCl₃) δ 9.03 (s, 1H), 7.28–7.20 (m, 4H), 6.97 (dd, J = 9.3, 2.8 Hz, 1H), 6.89 (td, J =8.5, 2.8 Hz, 1H), 6.65 (dd, J = 8.8, 4.7 Hz, 1H), 3.87 (q, J = 7.6Hz, 1H), 3.65 (td, J = 7.9, 5.3 Hz, 1H), 2.51–2.45 (m, 1H), 2.40

(s, 3H), 2.34–2.28 (m, 1H), 1.91–1.82 (m, 1H), 1.47–1.33 (m, 1H); $^{13}C{^{1}H}$ NMR (125 MHz, CDCl₃) δ 158.2 (d, *J* = 238.0 Hz), 153.0, 137.9, 135.1, 131.18, 131.16, 129.6, 125.6 (d, *J* = 6.8 Hz), 116.3 (d, *J* = 23.1 Hz), 115.8 (d, *J* = 7.8 Hz), 111.6 (d, *J* = 24.2 Hz), 96.8 (d, *J* = 1.8 Hz), 69.8, 39.3, 26.1, 21.4; ^{19}F NMR (470 MHz, CDCl₃) δ -124.18. IR (KBr, neat) 3205, 2982, 2924, 2870, 1671, 1610, 1506, 1417, 1390, 1264, 1171, 1051, 1024, 862, 815, 753, 642, 513 cm⁻¹; HRMS (ESI) calcd. for C₁₈H₁₈FN₂O₂ (M + H)⁺ 313.1347, found 313.1359.


(S)-6'-Chloro-3'-(p-tolyl)-4,5-dihydro-1'H,3H-spiro[furan-2,4'-quinazolin]-2'(3'H)-one (2f):



White solid; R_f (Hexane:EtOAc, 1:1) 0.50; mp 229-231 °C. Yield 126 mg, 96%; ¹H NMR (400 MHz, CDCl₃) δ 9.13 (s, 1H), 7.27–7.22 (m, 5H), 7.11 (dd, J = 8.5, 2.3 Hz, 1H), 6.61 (d, J = 8.5 Hz, 1H), 3.88 (q, J = 7.5 Hz, 1H), 3.65 (td, J = 7.9, 5.4 Hz, 1H), 2.51–2.44 (m, 1H), 2.41 (s, 3H), 2.35–2.27 (m,

1H), 1.91–1.82 (m, 1H), 1.45–1.34 (m, 1H); ${}^{13}C{}^{1}H$ NMR (125 MHz, CDCl₃) δ 152.9, 138.0, 135.1, 133.6, 131.2, 129.6, 129.2, 126.9, 125.8, 124.9, 116.0, 96.8, 69.8, 39.5, 26.0, 21.3. IR (KBr, neat) 3209, 2935, 1675, 1600, 1495, 1417, 1385, 1269, 1054, 880, 817, 751, 726, 645, 509 cm⁻¹; HRMS (ESI) calcd. for C₁₈H₁₈ClN₂O₂ (M + H)⁺ 329.1051, found 329.1051.


(*S*)-6'-Bromo-3'-(*p*-tolyl)-4,5-dihydro-1'*H*,3*H*-spiro[furan-2,4'-quinazolin]-2'(3'*H*)-one (2g):



White solid; R_f (Hexane:EtOAc, 1:1) 0.50; mp 239-241 °C. Yield 143 mg, 96%; ¹H NMR (400 MHz, CDCl₃) δ 8.98 (s, 1H), 7.37 (d, J = 2.2 Hz, 1H), 7.29–7.22 (m, 5H), 6.57 (d, J = 8.5 Hz, 1H), 3.89 (q, J = 7.6 Hz, 1H), 3.65 (td, J = 7.9, 5.4 Hz, 1H), 2.52–2.45 (m, 1H), 2.41 (s, 3H), 2.35–2.28 (m, 1H), 1.92–

1.82 (m, 1H), 1.45–1.34 (m, 1H); ${}^{13}C{}^{1}H$ NMR (125 MHz, CDCl₃) δ 152.8, 138.0, 135.0, 134.1, 132.1, 131.1, 129.7, 127.9, 126.3, 116.3, 114.2, 96.7, 69.9, 39.6, 26.0, 21.4. IR (KBr, neat) 3239, 3080, 2928, 2873, 1672, 1596, 1494, 1417, 1379, 1262, 1032, 941, 873, 820, 752, 642, 510 cm⁻¹; HRMS (ESI) calcd. for C₁₈H₁₈BrN₂O₂ (M + H)⁺ 373.0546, found 373.0547.


(*S*)-3'-(*p*-Tolyl)-6'-(trifluoromethyl)-4,5-dihydro-1'*H*,3*H*-spiro[furan-2,4'-quinazolin]-2'(3'*H*)-one (2h):



White solid; R_f (Hexane:EtOAc, 1:1) 0.50; mp 184-186 °C. Yield 136 mg, 94%; ¹H NMR (500 MHz, CDCl₃) δ 9.34 (s, 1H), 7.50 (s, 1H), 7.38 (d, J = 8.2 Hz, 1H), 7.31–7.23 (m, 4H), 6.73 (d, J = 8.3 Hz, 1H), 3.91 (t, J = 7.9 Hz, 1H), 3.67 (q, J = 7.3 Hz, 1H), 2.57–2.48 (m, 1H), 2.42 (s, 3H), 2.37–2.29 (m,

1H), 1.93–1.86 (m, 1H), 1.47–1.39 (m, 1H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 152.7, 138.2, 137.8, 134.8, 131.1, 129.7, 126.4 (q, *J* = 3.6 Hz), 124.6, 124.34 (q, *J* = 269.7 Hz), 124.26 (q, *J* = 32.6 Hz), 122.5 (q, *J* = 3.9 Hz), 114.9, 96.8, 70.0, 39.9, 26.0, 21.3. IR (KBr, neat) 3245, 2956, 2878, 1676, 1607, 1512, 1429, 1393, 1322, 1261, 1163, 1113, 1077, 1033, 836, 667, 509 cm⁻¹; HRMS (ESI) calcd. for C₁₉H₁₈F₃N₂O₂ (M + H)⁺ 363.1315, found 363.1315.


(S)-6'-Acetyl-3'-(p-tolyl)-4,5-dihydro-1'H,3H-spiro[furan-2,4'-quinazolin]-2'(3'H)-one (2i):



White solid; R_f (Hexane:EtOAc, 2:3) 0.50; mp 240-242 °C. Yield 87 mg, 65%; ¹H NMR (400 MHz, CDCl₃) δ 9.50 (s, 1H), 7.94 (d, J = 1.9 Hz, 1H), 7.76 (dd, J = 8.4, 1.9 Hz, 1H), 7.34–7.23 (m, 4H), 6.72 (d, J = 8.4 Hz, 1H), 3.93 (q, J = 7.7 Hz, 1H), 3.70 (td, J = 8.0, 5.1 Hz, 1H), 2.55 (s, 3H), 2.51–

2.44 (m, 1H), 2.42 (s, 3H), 2.40–2.37 (m, 1H), 1.94–1.89 (m, 1H), 1.43–1.33 (m, 1H). $^{13}C{^{1}H}$ NMR (125 MHz, CDCl₃) δ 196.5, 152.7, 139.2, 138.1, 135.0, 131.5, 131.1, 130.2, 129.7, 126.0, 124.3, 114.5, 96.9, 69.9, 39.6, 26.4, 26.1, 21.4. IR (KBr, neat) 3243, 2958, 2925, 1674, 1604, 1512, 1424, 1390, 1357, 1326, 1288, 1243, 1151, 1032, 829, 753, 642, 506 cm⁻¹; HRMS (ESI) calcd. for $C_{20}H_{21}N_2O_3$ (M + H)⁺ 337.1547, found 337.1547.


Methyl (*S*)-2'-oxo-3'-(*p*-tolyl)-2',3',4,5-tetrahydro-1'*H*,3*H*-spiro[furan-2,4'-quinazoline]-6'-carboxylate (2j):



White solid; R_f (Hexane:EtOAc, 2:3) 0.50; mp 258-260 °C. Yield 124 mg, 88%; ¹H NMR (400 MHz, CDCl₃) δ 9.41 (s, 1H), 7.97 (d, J = 1.8 Hz, 1H), 7.83 (dd, J = 8.4, 1.9 Hz, 1H), 7.27–7.23 (m, 4H), 6.68 (d, J = 8.4 Hz, 1H), 3.95–3.87 (m, 4H), 3.71 (td, J = 8.0, 5.0 Hz, 1H), 2.53–2.37 (m,

5H), 1.97–1.87 (m, 1H), 1.44–1.31 (m, 1H); ${}^{13}C{}^{1}H$ NMR (125 MHz, CDCl₃) δ 166.7, 152.7, 139.0, 138.1, 135.0, 131.1, 130.8, 129.7, 127.4, 124.0, 123.8, 114.5, 96.9, 69.8, 52.1, 39.5, 26.1, 21.3. IR (KBr, neat) 3250, 2951, 2877, 1716, 1676, 1614, 1513, 1422, 1389, 1293, 1244, 1110, 1033, 897, 846, 767, 667, 644, 514 cm⁻¹; HRMS (ESI) calcd. for C₂₀H₂₁N₂O₄ (M + H)⁺ 353.1496, found 353.1497.


(S)-5',6'-Dimethyl-3'-(*p*-tolyl)-4,5-dihydro-1'*H*,3*H*-spiro[furan-2,4'-quinazolin]-2'(3'*H*)one (2k):



White solid; R_f (Hexane:EtOAc, 1:1) 0.50; mp 180-182 °C. Yield 115 mg, 89%; ¹H NMR (400 MHz, CDCl₃) δ 9.41 (s, 1H), 7.97 (d, J = 1.8 Hz, 1H), 7.83 (dd, J = 8.4, 1.9 Hz, 1H), 7.27–7.23 (m, 4H), 6.68 (d, J = 8.4 Hz, 1H), 3.95–3.87 (m, 4H), 3.71 (td, J = 8.0, 5.0 Hz, 1H), 2.53–2.37 (m, 5H), 1.97–

1.87 (m, 1H), 1.44–1.31 (m, 1H); ${}^{13}C{}^{1}H$ NMR (125 MHz, CDCl₃) 152.9, 138.0, 137.7, 135.7, 132.7, 131.2, 130.4, 129.6, 125.8, 121.6, 115.3, 97.2, 69.5, 39.1, 26.2, 21.3, 19.6, 19.5. IR (KBr, neat) 3197, 2923, 2867, 1665, 1599, 1510, 1414, 1379, 1265, 1199, 1033, 867, 819, 732, 656, 565, 524, 463 cm⁻¹; HRMS (ESI) calcd. for $C_{20}H_{23}N_2O_2$ (M + H)⁺ 323.1754, found 323.1759.


(S)-3'-Phenyl-4,5-dihydro-1'H,3H-spiro[furan-2,4'-quinazolin]-2'(3'H)-one (2l):



White solid; R_f (Hexane:EtOAc, 1:1) 0.50; mp 198-200 °C. Yield 108 mg, 96%; ¹H NMR (400 MHz, CDCl₃) δ 8.83–8.57(m, 1H), 7.46–7.37 (m, 5H), 7.29 (d, J = 7.8 Hz, 1H), 7.23–7.18 (m, 1H), 7.01 (t, J = 7.6 Hz, 1H), 6.72 (d, J = 7.9 Hz, 1H), 3.88 (q, J = 7.6 Hz, 1H), 3.68 (td, J = 8.0, 5.1 Hz, 1H), 2.52–2.44 (m, 1H), 2.43–2.35 (m, 1H), 1.90–1.82

(m, 1H), 1.38–1.31 (m, 1H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 152.8, 138.1, 134.8, 131.6, 129.3, 128.9, 128.0, 125.0, 124.3, 122.2, 114.4, 97.2, 69.6, 39.3, 26.1. IR (KBr, neat) 3204, 3057, 2977, 2925, 2873, 1664, 1600, 1491, 1407, 1323, 1269, 1191, 1033, 989, 809, 752, 704, 642, 546 cm⁻¹; HRMS (ESI) calcd. for C₁₇H₁₇N₂O₂ (M + H)⁺ 281.1285, found 281.1303.


(S)-6'-Butyl-3'-phenyl-4,5-dihydro-1'*H*,3*H*-spiro[furan-2,4'-quinazolin]-2'(3'*H*)-one (2m):



White solid; R_f (Hexane:EtOAc, 3:2) 0.50; mp 156-158 °C. Yield 133 mg, 99%; ¹H NMR (500 MHz, CDCl₃) δ 8.57–8.42 (m, 1H), 7.47–7.37 (h, *J* = 7.0, 6.0 Hz, 5H), 7.07 (s, 1H), 7.03 (d, *J* = 7.85 Hz, 1H), 6.65 (d, *J* = 8.1 Hz, 1H), 3.89 (q, *J* = 7.7 Hz, 1H), 3.67

(td, J = 8.0, 5.1 Hz, 1H), 2.57 (t, J = 7.8 Hz, 2H), 2.50–2.44 (m, 1H), 2.42–2.36 (m, 1H), 1.91– 1.83 (m, 1H), 1.61–1.54 (m, 2H), 1.40–1.31 (m, 3H), 0.93 (t, J = 7.4 Hz, 3H); ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 152.8, 138.3, 136.8, 132.6, 131.6, 129.4, 128.8, 128.0, 124.6, 124.1, 114.3, 97.3, 69.6, 39.3, 35.4, 33.9, 26.1, 22.4, 14.0. IR (KBr, neat) 3209, 3050, 2955, 2928, 2866, 1669, 1607, 1514, 1423, 1392, 1266, 1192, 1030, 828, 734, 703, 646, 550 cm⁻¹; HRMS (ESI) calcd. for C₂₁H₂₅N₂O₂ (M + H)⁺ 337.1911, found 337.1911.


(S)-6'-Fluoro-3'-phenyl-4,5-dihydro-1'*H*,3*H*-spiro[furan-2,4'-quinazolin]-2'(3'*H*)-one (2n):



White solid; R_{*f*} (Hexane:EtOAc, 1:1) 0.50; mp 247-249 °C. Yield 116 mg, 97%; ¹H NMR (400 MHz, CDCl₃/DMSO-d₆) δ 8.95 (s, 1H), 7.41–7.32 (m, 5H), 6.95 (dd, *J* = 9.4, 2.7 Hz, 1H), 6.90 (td, *J* = 8.4, 2.7 Hz, 1H), 6.74 (dd, *J* = 8.8, 4.7 Hz, 1H), 3.84 (q, *J* = 7.7 Hz, 1H),

3.64–3.58 (m, 1H), 2.48–2.41 (m, 1H), 2.34–2.26 (m, 1H), 1.88–1.78 (m, 1H), 1.39–1.28 (m, 1H). ${}^{13}C{}^{1}H{}$ NMR (125 MHz, CDCl₃/DMSO-d₆) δ 158.1 (d, *J* = 238.1 Hz), 152.5, 137.9, 131.5, 131.3, 128.8, 128.0, 125.5 (d, *J* = 6.8 Hz), 116.2 (d, *J* = 22.9 Hz), 115.6 (d, *J* = 7.8 Hz), 111.5 (d, *J* = 24.3 Hz), 96.8, 69.6, 39.2, 25.9. ${}^{19}F$ NMR (470 MHz, CDCl₃/C₆F₆) δ -123.9. IR (KBr, neat) 3202, 2923, 2853, 1663, 1506, 1425, 1393, 1262, 1191, 1034, 794, 754, 707, 645, 552 cm⁻¹; HRMS (ESI) calcd. for C₁₇H₁₆FN₂O₂ (M + H)⁺ 299.1190, found 299.1191.


(S)-7'-Methyl-3'-phenyl-4,5-dihydro-1'*H*,3*H*-spiro[furan-2,4'-quinazolin]-2'(3'*H*)-one (20):



White solid; R_f (Hexane:EtOAc, 1:1) 0.50; mp 218-220 °C. Yield 115 mg, 98%; ¹H NMR (400 MHz, CDCl₃) δ 8.10 (s, 1H), 7.49–7.33 (m, 5H), 7.19 (d, J = 8.0 Hz, 1H), 6.85 (d, J = 8.0 Hz, 1H), 6.56 (s, 1H), 3.77 (s, 2H), 2.42 (t, J = 7.8 Hz, 2H), 2.30 (s, 3H),

2.08–1.71 (m, 1H), 1.52–1.20 (m, 1H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 152.7, 139.7, 138.2, 134.7, 131.5, 128.9, 128.1, 125.1, 123.4, 121.5, 114.6, 69.4, 39.0, 26.2, 21.2. IR (KBr, neat) 3209, 2974, 2872, 1667, 1595, 489, 1411, 1270, 1189, 1031, 871, 805, 702, 523, 458 cm⁻¹; HRMS (ESI) calcd. for C₁₈H₁₉N₂O₂ (M + H)⁺ 295.1441, found 295.1447.


(S)-7'-Chloro-3'-phenyl-4,5-dihydro-1'*H*,3*H*-spiro[furan-2,4'-quinazolin]-2'(3'*H*)-one (2p):



White solid; R_f (Hexane:EtOAc, 1:1) 0.50; mp 245-247 °C. Yield 122 mg, 97%; ¹H NMR (400 MHz, CDCl₃) δ 8.91 (s, 1H), 7.48–7.34 (m, 5H), 7.20 (d, J = 8.4 Hz, 1H), 6.97 (dd, J = 8.4, 2.1 Hz, 1H), 6.73 (d, J = 2.1 Hz, 1H), 3.87 (q, J = 7.6 Hz, 1H), 3.65 (td, J

= 8.0, 5.3 Hz, 1H), 2.52–2.45 (m, 1H), 2.32 (dt, J = 14.1, 8.3 Hz, 1H), 1.90–1.80 (m, 1H), 1.41– 1.30 (m, 1H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 152.7, 137.7, 136.0, 134.9, 131.4, 129.0, 128.3, 126.4, 122.9, 122.3, 114.3, 96.9, 69.8, 39.5, 26.0. IR (KBr, neat) 3211, 2961, 2872, 1674, 1596, 1493, 1413, 1377, 1315, 1251, 1087, 1035, 953, 865, 803, 764, 701, 575, 487, 447 cm⁻¹; HRMS (ESI) calcd. for C₁₇H₁₆ClN₂O₂ (M + H)⁺ 315.0895, found 315.0895.


(*S*)-3'-(4-Methoxyphenyl)-4,5-dihydro-1'*H*,3*H*-spiro[furan-2,4'-quinazolin]-2'(3'*H*)-one (2q):



White solid; R_f (Hexane:EtOAc, 3:7) 0.40; mp 267-269 °C. Yield 123 mg, 99%; ¹H NMR (400 MHz, CDCl₃/DMSO-d₆) δ 8.37 (s, 1H), 7.38–7.27 (m, 3H), 7.23 (td, J = 7.6, 1.4 Hz, 1H), 7.02 (td, J = 7.6, 1.2 Hz, 1H), 6.94 (dt, J = 9.1, 1.4 Hz, 2H), 6.78 (dd, J = 8.1,

1.2 Hz, 1H), 3.88 (q, J = 7.7 Hz, 1H), 3.84 (s, 3H), 3.71 (td, J = 7.9, 5.1 Hz, 1H), 2.51–2.36 (m, 2H), 1.93–1.84 (m, 1H), 1.45–1.34 (m, 1H). ¹³C{¹H} NMR (125 MHz, CDCl₃/DMSO-d₆) δ 159.1, 152.7, 134.9, 132.4, 130.7, 129.3, 125.1, 124.2, 122.1, 114.2, 114.1, 97.2, 69.6, 55.5, 39.2, 26.1. IR (KBr, neat) 3189, 2919, 1660, 1602, 1506, 1429, 1243, 1171, 1033, 821, 756, 667, 538 cm⁻¹; HRMS (ESI) calcd. for C₁₈H₁₉N₂O₃ (M + H)⁺ 311.1390, found 311.1391.


(S)-3'-(4-(Trifluoromethyl)phenyl)-4,5-dihydro-1'*H*,3*H*-spiro[furan-2,4'-quinazolin]-2'(3'*H*)-one (2r):



White solid; R_{*f*} (Hexane:EtOAc, 1:1) 0.50; mp 268-270 °C. Yield 127 mg, 91%; ¹H NMR (400 MHz, CDCl₃) δ 8.67 (s, 1H), 7.71 (d, *J* = 8.3 Hz, 2H), 7.57 (d, *J* = 8.2 Hz, 2H), 7.30 (d, *J* = 7.9 Hz, 1H), 7.24 (td, *J* = 7.7, 1.4 Hz, 1H), 7.05 (td, *J* = 7.6, 0.9 Hz, 1H), 6.73 (d, *J* = 7.9 Hz, 1H), 3.91 (q, *J* = 7.4 Hz, 1H), 3.66 (td, *J* = 7.8, 5.3

Hz, 1H), 2.42 (d, J = 6.3 Hz, 1H), 2.40 (d, J = 7.0 Hz, 1H), 1.96–1.87 (m, 1H), 1.44–1.33 (m, 1H); ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 152.6, 141.6, 134.5, 132.1, 130.2 (q, J = 32.4 Hz), 129.5, 125.9 (q, J = 3.7 Hz), 124.9, 124.3, 124.2 (q, J = 270.5 Hz), 122.6, 114.5, 97.3, 69.7, 39.4, 26.0. ¹⁹F NMR (470 MHz, CDCl₃/C₆F₆) δ -65.7. IR (KBr, neat) 3209, 3066, 2925, 1671, 1601, 1501, 1403, 1321, 1269, 1162, 119, 1064, 1022, 934, 748, 704, 640, 584 cm⁻¹; HRMS (ESI) calcd. for C₁₈H₁₆F₃N₂O₂ (M + H)⁺ 349.1158, found 349.1158.


(S)-3'-Benzyl-6'-butyl-4,5-dihydro-1'H,3H-spiro[furan-2,4'-quinazolin]-2'(3'H)-one (2s):



White solid; R_f (Hexane:EtOAc, 3:2) 0.50; mp 156-158 °C. Yield 137 mg, 98%; ¹H NMR (500 MHz, CDCl₃) δ 9.05 (s, 1H), 7.39 (d, J = 7.6 Hz, 2H), 7.29 (t, J = 7.6 Hz, 2H), 7.21 (t, J = 7.4 Hz, 1H), 7.00 (s, 1H), 6.97 (d, J = 8.2 Hz, 1H), 6.53 (d, J = 8.0 Hz, 1H), 4.80 (d, J = 15.5 Hz, 1H), 4.65 (d, J = 15.5

Hz, 1H), 4.25–4.17 (m, 2H), 2.56 (t, J = 7.8 Hz, 2H), 2.33–2.27 (m, 1H), 2.23–2.17 (m, 1H), 2.14–2.03 (m, 2H), 1.57 (p, J = 7.5 Hz, 2H), 1.36 (h, J = 7.4 Hz, 2H), 0.93 (t, J = 7.4 Hz, 3H); ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 154.2, 139.9, 136.6, 132.2, 129.1, 128.3, 127.3, 126.7, 125.0, 124.0, 114.0, 96.9, 70.2, 45.4, 39.1, 35.3, 34.0, 25.6, 22.5, 14.1. IR (KBr, neat) 3194, 3042, 2927, 2867, 1663, 1605, 1511, 1436, 1401, 1354, 1263, 1050, 953, 825, 707, 643, 599, 506 cm⁻¹; HRMS (ESI) calcd. for C₂₂H₂₇N₂O₂ (M + H)⁺ 351.2067, found 351.2070.

(*S*)-3'-((1*r*,4*S*)-4-Methylcyclohexyl)-4,5-dihydro-1'*H*,3*H*-spiro[furan-2,4'-quinazolin]-2'(3'*H*)-one (2t):




White solid; R_f (Hexane:EtOAc, 3:2) 0.50; mp 203-205 °C. Yield 101 mg, 84%; ¹H NMR (500 MHz, CDCl₃) δ 8.13 (s, 1H), 7.20– 7.17 (m, 2H), 6.95 (t, *J* = 7.6 Hz, 1H), 6.71 (d, *J* = 8.1 Hz, 1H), 4.23–4.24 (m, 2H), 3.27 (s, 1H), 2.82 (q, *J* = 12.6 Hz, 1H), 2.43 (qd, *J* = 12.5, 3.6 Hz, 1H), 2.38–2.31 (m, 1H), 2.21–2.12 (m, 3H),

1.84–1.75 (m, 2H), 1.74–1.71 (m, 1H), 1.69–1.65 (m, 1H), 1.53–1.43 (m, 1H), 1.04–0.95 (m, 2H), 0.90 (d, J = 6.5 Hz, 3H); ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 152.4, 134.7, 129.0, 125.5,

124.6, 121.7, 113.2, 97.7, 70.8, 55.6, 41.0, 36.0, 35.8, 31.9, 30.7, 30.6, 25.8, 22.6. IR (KBr, neat) 3195, 3058, 2916, 1663, 1605, 1501, 1438, 1375, 1268, 1041, 750, 578, 465 cm⁻¹; HRMS (ESI) calcd. for $C_{18}H_{25}N_2O_2$ (M + H)⁺ 301.1911, found 301.1919.


5-Ethyl-6'-methyl-3'-(*p*-tolyl)-4,5-dihydro-1'*H*,3*H*-spiro[furan-2,4'-quinazolin]-2'(3'*H*)one (2u):



White solid; R_f (Hexane:EtOAc, 3:2) 0.50; mp 214-216 °C. Yield 133 mg, 99% (d.r. = 1:1); ¹H NMR (500 MHz, CDCl₃) δ 8.46 (d, J = 13.5 Hz, 0.5H), 8.37 (d, J = 13.2 Hz, 0.5H), 7.29 (d, J = 8.0 Hz, 2H), 7.22 (d, J = 8.0 Hz, 2H), 7.10 (s, 1H), 7.01 (t, J = 6.9 Hz, 1H), 6.62 (t, J = 7.9 Hz, 1H), 3.96–3.90

(m, 0.5H), 3.38–3.33 (m, 0.5H), 2.58–2.53 (m, 0.5H), 2.51–2.47 (m, 1H), 2.41 (s, 3H), 2.33 (s, 1.5H), 2.32 (s, 1.5H), 2.30–2.23 (m, 0.5H), 1.89–1.83 (m, 0.5H), 1.77–1.39 (m, 3H), 1.27–1.19 (m, 0.5H), 0.87 (t, J = 7.4 Hz, 1.5H), 0.84 (t, J = 7.5 Hz, 1.5H). $^{13}C{^{1}H}$ NMR (125 MHz, CDCl₃) δ 153.05, 152.97, 137.8, 137.6, 135.5, 135.1, 132.5, 132.2, 131.7, 131.5, 131.4, 129.9, 129.8, 129.4, 129.3, 125.24, 125.19, 125.0, 124.5, 114.4, 114.2, 97.1, 96.5, 82.6, 40.2, 39.3, 31.5, 31.4, 28.7, 28.0, 21.3, 21.2, 10.6, 10.4. IR (KBr, neat) 3212, 3037, 2962, 2925, 1671, 1605, 1512, 1421, 1390, 1266, 1024, 820, 756, 641, 515, 437 cm⁻¹; HRMS (ESI) calcd. for C₂₁H₂₅N₂O₂ (M + H)⁺ 337.1911, found 337.1913.


6'-Chloro-5-ethyl-3'-phenyl-4,5-dihydro-1'*H*,3*H*-spiro[furan-2,4'-quinazolin]-2'(3'*H*)one (2v):



White solid; R_{*f*} (Hexane:EtOAc, 1:1) 0.60; mp 152-154 °C. Yield 132 mg, 96% (d.r. = 1:1); ¹H NMR (500 MHz, CDCl₃) δ 9.28–9.24 (m, 0.5H), 9.18–9.15 (m, 0.5H), 7.46–7.36 (m, 5H), 7.26–7.24 (m, 1H), 7.12–7.09 (m, 1H), 6.61 (dd, *J* = 8.5, 3.8 Hz, 1H), 3.96–3.90 (m. 0.5H), 3.29–3.24 (m, 0.5H), 2.57–2.48 (m,

1H), 2.43–2.36 (m, 0.5H), 2.29–2.24 (m, 0.5H), 1.97–1.82 (m, 1H), 1.72–1.67 (m, 0.5H), 1.66– 1.60 (m, 0.5H), 1.59–1.52 (m, 0.5H), 1.48–1.38 (m, 1H), 1.22–1.13 (m, 0.5H), 0.86 (t, J = 7.4 Hz, 2H), 0.82 (t, J = 7.5 Hz, 2H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 152.94, 152.88, 137.9, 137.3, 133.6, 133.4, 132.0, 129.2, 129.1, 128.8, 128.7, 128.3, 128.1, 127.1, 126.9, 126.8, 126.3, 124.8, 116.1, 115.9, 96.6, 96.1, 83.03, 82.97, 40.4, 39.7, 31.3, 31.2, 28.6, 27.9, 10.6, 10.4. IR (KBr, neat) 3250, 2964, 2930, 2873, 1673, 1597, 1494, 1415, 1381, 1261, 1086, 981, 943, 822, 753, 702, 639, 554 cm⁻¹; HRMS (ESI) calcd. for $C_{19}H_{20}ClN_2O_2$ (M + H)⁺ 343.1208, found 343.1211.


3'-Benzyl-5-ethyl-4,5-dihydro-1'H,3H-spiro[furan-2,4'-quinazolin]-2'(3'H)-one (2w):



White solid; R_f (Hexane:EtOAc, 3:2) 0.50; mp 205-207 °C. Yield 126 mg, 98% (d.r. = 3:2); ¹H NMR (400 MHz, CDCl₃) δ 9.16–9.04 (m, 1H, minor), 8.97–8.85 (m, 1H, major), 7.41 (d, *J* = 7.3 Hz, 2H, major), 7.35 (d, *J* = 7.4 Hz, 2H, minor), 7.30–7.25 (m, 3H), 7.22–7.17 (m, 1H), 7.17–7.11 (m, 1H), 6.99–6.94 (m, 1H), 6.61 (d, *J* =

7.9, 1H, minor), 6.58 (d, J = 7.9, 1H, major), 4.96 (d, J = 16.0 Hz, 1H, minor), 4.88 (d, J = 15.3 Hz, 1H), 4.63 (d, J = 16.0 Hz, 1H, minor), 4.53 (d, J = 15.3 Hz, 1H, major), 4.25–4.13 (m, 1H), 2.44–2.28 (m, 3H, minor), 2.20–2.04 (m, 3H, major), 1.89–1.75 (m, 1H), 1.70–1.56 (m, 2H), 0.98 (t, J = 7.4 Hz, 3H, major), 0.95 (t, J = 7.4 Hz, 3H, minor). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 154.0, 153.8, 139.9, 134.5, 134.4, 129.1, 129.0, 128.4, 128.3, 127.7, 127.0, 126.7, 126.6, 125.8, 125.0, 124.7, 124.6, 122.0, 114.3, 113.9, 96.5, 96.4, 83.8, 82.4, 45.4, 45.3, 40.5, 38.9, 31.2, 31.1, 28.7, 28.6, 10.7, 10.5. IR (KBr, neat) 3198, 3122, 3057, 2965, 2922, 2873, 1664, 1501, 1494, 1435, 1404, 1355, 1321, 1266, 1174, 1061, 1027, 944, 848, 807, 754, 735, 698, 653, 601, 503 cm⁻¹; HRMS (ESI) calcd. for C₂₀H₂₃N₂O₂ (M + H)⁺ 323.1754, found 323.1758.

5-Cyclohexyl-3'-(*p*-tolyl)-4,5-dihydro-1'*H*,3*H*-spiro[furan-2,4'-quinazolin]-2'(3'*H*)-one (2x):




White solid; R_f (Hexane:EtOAc, 7:3) 0.50; mp 226-228 °C. Yield 148 mg, 98% (d.r. = 3:2); ¹H NMR (500 MHz, CDCl₃) δ 8.63 (s, 1H, minor), 8.57 (s, 1H, major), 7.32 (d, J = 7.7 Hz, 3H, minor), 7.29 (d, J = 7.8 Hz, 3H, major), 7.23 (d, J = 7.7 Hz, 2H), 7.19 (t, J = 7.7 Hz, 1H), 7.02–6.98 (m, 1H), 6.72 (t, J

= 7.5 Hz, 1H), 3.67–3.62 (m, 1H, minor), 3.07–3.03 (m, 1H, major), 2.55–2.45 (m, 1H), 2.42 (s, 3H), 2.40–2.35 (m, 1H, minor), 2.30–2.25 (m, 1H, major), 1.97–1.92 (m, 1H), 1.85–1.79 (m, 1H, minor), 1.72–1.61 (m, 4H), 1.49 (d, J = 13.0 Hz, 1H, major), 1.42–1.34 (m, 1H), 1.26–1.07 (m, 3H), 1.03–0.75 (m, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 153.1, 153.0, 137.8, 137.6, 135.5, 134.9, 134.8, 134.5, 131.8, 129.4, 129.3, 129.00, 128.98, 125.5, 125.1, 125.0, 124.9, 122.1, 122.0, 114.4, 114.2, 96.5, 96.2, 85.64, 85.56, 43.0, 42.9, 40.2, 39.4, 30.6, 30.1, 29.9, 29.8, 29.0, 28.8, 26.54, 26.51, 26.04, 26.02, 25.82, 25.78, 21.4, 21.3. IR (KBr, neat) 3211,

3057, 2922, 285, 1669, 16001503, 1403, 1322, 1265, 1175, 1106, 1025, 866, 814, 786, 750, 702, 658, 508 cm⁻¹; HRMS (ESI) calcd. for $C_{24}H_{29}N_2O_2$ (M + H)⁺ 377.2224, found 377.2225.


(S)-3'-(p-Tolyl)-3,4,5,6-tetrahydro-1'H-spiro[pyran-2,4'-quinazolin]-2'(3'H)-one (2aa):



White solid; R_f (Hexane:EtOAc, 2:3) 0.40; mp 168-170 °C. Yield 121 mg, 98%; ¹H NMR (400 MHz, CDCl₃) δ 7.84 (d, J = 8.0 Hz, 1H), 7.54 (d, J = 7.7 Hz, 2H), 7.34 (t, J = 7.7 Hz, 1H), 7.30–7.27 (m, 3H), 7.09 (t, J = 7.7 Hz, 1H), 6.84 (d, J = 8.0 Hz, 1H), 4.35 (dd, J = 13.1, 6.2 Hz, 1H), 3.68–3.62 (m, 1H), 3.54 (td, J = 11.5, 2.9 Hz,

1H), 2.91–2.80 (m, 1H), 2.53–2.33 (m, 5H), 1.81–1.66 (m, 2H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 153.5, 138.5, 135.9, 134.6, 131.0, 129.9, 129.7, 127.7, 120.6, 119.5, 115.1, 89.5, 62.1, 34.6, 29.5, 27.9, 21.5. IR (KBr, neat) 3222, 3061, 2941, 1675, 1597, 1495, 1401, 1266, 1166, 1073, 1025, 870, 753, 704, 567 cm⁻¹; HRMS (ESI) calcd. for C₁₉H₂₁N₂O₂ (M + H)⁺ 309.1598, found 309.1598.

(S)-6'-Ethyl-3'-(p-tolyl)-3,4,5,6-tetrahydro-1'H-spiro[pyran-2,4'-quinazolin]-2'(3'H)-one (2ab):



White solid; R_f (Hexane:EtOAc, 2:3) 0.40; mp 154-156°C. Yield 132 mg, 98%; ¹H NMR (500 MHz, CDCl₃) δ 7.54 (s, 1H), 7.33 (s, 1H), 7.23–7.09 (m, 4H), 7.06 (dd, J = 8.1, 1.8 Hz, 1H), 6.68 (d, J = 8.0 Hz, 1H), 3.45–3.41 (m, 1H), 3.29–3.22 (m, 1H), 2.60 (q, J = 7.6 Hz, 2H), 2.32 (s, 3H), 2.03–1.91 (m,

2H), 1.86–1.77 (m, 1H), 1.67–1.61 (m, 1H), 1.55–1.50 (m, 1H), 1.46–1.37 (m, 1H), 1.19 (t, J = 7.6 Hz, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 154.4, 137.8, 137.4, 136.1, 133.7, 131.0, 129.7, 128.6, 124.6, 123.7, 114.7, 87.2, 62.6, 30.3, 28.7, 24.0, 21.4, 20.2, 16.1. IR (KBr, neat) 2960, 2931, 2870, 1671, 1601, 1510, 1423, 1391, 1265, 1074, 1029, 1006, 823, 757, 658, 515 cm⁻¹; HRMS (ESI) calcd. for C₂₁H₂₅N₂O₂ (M + H)⁺ 337.1911, found 337.1911.


Experimental procedure for gram-scale synthesis of compound 21:

To an ice-cold suspension of 1-(2-(4-hydroxybut-1-yn-1-yl)phenyl)-3-phenylurea (11) (1.0 g, 3.6 mmol, 1.0 equiv.) in DCM (15.0 mL), triflic acid (0.6 mL, 7.2 mmol, 2.0 equiv.) was added slowly under N₂ atmosphere. The reaction was continued to stir for 4.5 h at room temperature, and the progress of the reaction was monitored by TLC. It was then treated with saturated NaHCO₃ solution, and the organic layer was extracted with DCM (2 x 30 mL). The combined organic layers were further washed with brine, followed by drying over anhydrous Na₂SO₄.

The organic phase was concentrated in a rotary evaporator to give the crude product, which was then subjected to column chromatography over silica gel to provide the final product **2l** as a white solid in 92% yield (930 mg).


Experimental procedure and characterization data of compound 5:

Schematic representation of starting material 5:



To a mixture of Pd(PPh₃)₂Cl₂ (0.04 mmol, 0.04 equiv.), CuI (0.02 mmol, 0.02 equiv.) and 1-(2iodophenyl)-3-phenylurea (C) (1.0 mmol, 1.0 equiv.) in dry THF (5.0 mL) under N₂ atmosphere, triethylamine (5.0 mmol, 5.0 equiv.) was added. The reaction mixture was stirred for 10 minutes at room temperature, after which 1-hexyne (E) (1.2 mmol, 1.2 equiv.) was added dropwise over a period of 5 minutes. The reaction mixture was stirred for 5.0 hours (monitored by TLC analysis) before filtering through a pad of celite. The solids were washed with ethyl acetate, and the combined filtrates were concentrated in a rotary evaporator. The crude product was then purified by column chromatography to provide the corresponding product 5 in 96% yield (281 mg).

1-(2-(Hex-1-yn-1-yl)phenyl)-3-phenylurea (5):



White solid; R_f (Hexane:EtOAc, 4:1) 0.60; mp 142-144°C. Yield 281 mg, 96%. ¹H NMR (400 MHz, CDCl₃) δ 8.13 (d, J = 8.3 Hz, 1H), 7.44 (s, 1H), 7.33–7.29 (m, 4H), 7.25 (dd, J = 7.7, 1.6 Hz, 1H), 7.22–7.16 (m, 2H), 7.15–7.08 (m, 1H), 6.88 (t, J =

7.5 Hz, 1H), 2.17 (t, J = 6.8 Hz, 2H), 1.41–1.28 (m, 4H), 0.84 (t, J = 7.1 Hz, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 153.2, 139.6, 137.7, 137.7, 131.9, 129.6, 129.0, 125.30, 125.27, 123.1, 122.5, 118.92, 118.89, 112.9, 97.6, 76.1, 30.8, 22.2, 19.3, 13.7. IR (KBr, neat) 3327, 2957, 2928, 2870, 1657, 1600, 1579, 1549, 1499, 1446, 1303, 1250, 1214, 751, 693, 508 cm⁻¹. HRMS (ESI) calcd. for C₁₉H₂₁N₂O (M + H)⁺ 293.1648, found 293.1647.

Experimental procedure of control experiment:


Experimental procedure of scheme 3a:

To an ice-cold solution of 4-(2-(3-phenylureido)phenyl)but-3-yn-1-yl 4-methylbenzene-sulfonate (3) (174 mg, 0.4 mmol, 1.0 equiv) in DCM (4.0 mL), triflic acid (0.07 mL, 0.8 mmol, 2.0 equiv.) was added slowly under N₂ atmosphere. The reaction was continued to stir for 5 h at room temperature, and the progress of the reaction was monitored by TLC. To collect the starting material, the reaction mixture was treated with saturated NaHCO₃ solution, and the organic layer was extracted with DCM (2 x 10 mL). The combined organic layers were further washed with brine, followed by drying over anhydrous Na₂SO₄. The organic phase was concentrated in a rotary evaporator which was then subjected to column chromatography over silica gel to get the unreacted starting material **3** in 86% yield.

Experimental procedure of scheme 3b:

To an ice-cold solution of 1-(2-(hex-1-yn-1-yl)phenyl)-3-phenylurea (5) (117 mg, 0.4 mmol, 1.0 equiv) in DCM (4.0 mL), triflic acid (0.07 mL, 0.8 mmol, 2.0 equiv.) was added slowly under N_2 atmosphere. The reaction was continued to stir for 5 h at room temperature, and the progress of the reaction was monitored by TLC. To collect the starting material, the reaction mixture was treated with saturated NaHCO₃ solution, and the organic layer was extracted with DCM (2 x 10 mL). The combined organic layers were further washed with brine, followed by drying over anhydrous Na₂SO₄. The organic phase was concentrated in a rotary evaporator which was then subjected to column chromatography over silica gel to get the unreacted starting material **5** in 83% yield.


General experimental procedure and characterization data of the compounds 7a and 7b: Schematic representation of starting materials 7a and 7b:



To a solution of substituted 2-iodoaniline **A** (2.0 mmol, 1.0 equiv.) in DCM (5.0 mL) under N_2 atmosphere, substituted phenyl isocyanate **B** (2.2 mmol, 1.1 equiv.) was added dropwise. The reaction mixture was stirred overnight at room temperature to obtain a white precipitate, which was then filtered and washed with n-hexane to obtain a substituted 1,3-diphenyl urea **C**.

To a mixture of Pd(PPh₃)₂Cl₂ (0.04 mmol, 0.04 equiv.), CuI (0.02 mmol, 0.02 equiv.) and iodo substituted 1,3-diphenyl urea derivatives **C** (1.0 mmol, 1.0 equiv.) in dry THF (5.0 mL) under N₂ atmosphere, triethylamine (5.0 mmol, 5.0 equiv.) was added. The reaction mixture was stirred for 10 minutes at room temperature, after which homo propargylic sulfonamide **F** (1.2 mmol, 1.2 equiv.) in dry THF (1.0 mL) was added dropwise over a period of 5 minutes. The reaction mixture was stirred for 3.0 hours (monitored by TLC analysis) before filtering through a pad of celite. The solids were washed with ethyl acetate, and the combined filtrates were concentrated in a rotary evaporator. The crude product was then purified by column chromatography to provide the corresponding product 7.


4-Methyl-N-(4-(2-(3-(p-tolyl)ureido)phenyl)but-3-yn-1-yl)benzenesulfonamide (7a):



White solid; R_f (Hexane:EtOAc, 1:1) 0.50; mp 154-156 °C. Yield 439 mg, 98%. ¹H NMR (500 MHz, CDCl₃) δ 8.25 (d, J = 8.4 Hz, 1H), 7.84 (d, J = 11.7 Hz, 1H), 7.75 (d, J = 7.8 Hz, 2H), 7.65 (s, 1H), 7.35 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 7.7 Hz, 1H),

7.26 (d, J = 8.2 Hz, 3H), 7.06 (d, J = 8.0 Hz, 2H), 6.92 (t, J = 7.6 Hz, 1H), 5.56–5.46 (m, 1H), 3.15–3.10 (m, 2H), 2.64–2.59 (m, 2H), 2.40 (s, 3H), 2.28 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 153.3, 144.1, 140.5, 136.6, 136.2, 133.0, 132.0, 130.1, 129.6, 129.3, 127.0, 122.1, 120.7, 119.4, 120.0, 92.9, 78.6, 41.9, 21.7, 21.6, 20.9. IR (KBr, neat) 3359, 2922, 1677, 1600, 1578, 1531, 1515, 1446, 1301, 1247, 1202, 1154, 1092, 917, 814, 753, 662, 548, 507 cm⁻¹. HRMS (ESI) calcd. for C₂₅H₂₆N₃O₃S (M + H)⁺ 448.1689, found 448.1689.

N-(4-(2-(3-(4-Methoxyphenyl)ureido)phenyl)but-3-yn-1-yl)-4-methylbenzenesulfonamide (7b):




White solid; R_f (Hexane:EtOAc, 1:1) 0.40; mp 120-122 °C. Yield 445 mg, 96%. ¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, *J* = 8.4 Hz, 1H), 7.70 (d, *J* = 7.9 Hz, 3H), 7.57 (s, 1H), 7.31 (d, *J* = 8.4 Hz, 2H), 7.24–7.18 (m, 4H), 6.87 (t, *J* = 7.5 Hz, 1H),

6.76 (d, J = 8.3 Hz, 2H), 5.62 (s, 1H), 3.72 (s, 3H), 3.06 (s, 2H), 2.54 (t, J = 5.8 Hz, 2H), 2.36 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 156.2, 153.6, 144.0, 140.4, 136.6, 132.0, 131.5, 130.0, 129.9, 129.2, 127.1, 127.0, 123.1, 122.0, 119.2, 114.4, 111.9, 92.9, 78.5, 55.6, 41.9, 21.62, 21.57. IR (KBr, neat) 3361, 2932, 1674, 1601, 1579, 1532, 1508, 1445, 1301, 1241, 1211, 1153, 1091, 1035, 813, 753, 735, 661, 547 cm⁻¹. HRMS (ESI) calcd. for C₂₅H₂₆N₃O₄S (M + H)⁺ 464.1639, found 464.1636.

General experimental procedure and characterization data of the compounds 8a and 8b:

To an ice-cold suspension of alkynyl-benzenesulfonamide substituted diphenyl urea 7 (0.4 mmol, 1.0 equiv.) in DCM (4.0 mL), triflic acid (1.2 mmol, 3.0 equiv.) was added under N_2 atmosphere. The reaction was continued to stir at room temperature for 48 h. It was then treated with saturated NaHCO₃ solution, and the organic layer was extracted with DCM (2 x 10 mL). The combined organic layers were further washed with brine, followed by drying over anhydrous Na₂SO₄. The organic phase was concentrated in a rotary evaporator to give the crude product, which was then subjected to column chromatography over silica gel to provide the final product **8**.


(S)-3'-(p-Tolyl)-1-tosyl-1'H-spiro[pyrrolidine-2,4'-quinazolin]-2'(3'H)-one (8a):



White solid; R_f (Hexane:EtOAc, 2:3) 0.50; mp 220-222 °C. Yield 161 mg, 90%; ¹H NMR (500 MHz, CDCl₃/DMSO-d₆) δ 9.05 (s, 1H), 7.73 (d, J = 8.1 Hz, 1H), 7.25–7.23 (m, 1H), 7.14 (d, J = 8.2Hz, 1H), 7.06 (t, J = 7.8 Hz, 2H), 6.90 (d, J = 7.3 Hz, 2H), 6.85–

6.78 (m, 3H), 6.45–6.35 (m, 2H), 3.60 (t, J = 8.7 Hz, 1H), 3.09 (q, J = 8.2 Hz, 1H), 2.61 (dd, J = 14.1, 8.1 Hz, 1H), 2.52–2.46 (m, 1H), 2.42–2.37 (m, 1H), 2.32 (s, 3H), 2.25 (s, 3H), 0.81–0.71 (m, 1H). ¹³C{¹H} NMR (125 MHz, CDCl₃/DMSO-d₆) δ 151.7, 142.3, 137.8, 137.1, 136.5, 135.5, 131.4, 131.1, 130.1, 129.4, 129.0, 128.8, 126.5, 126.4, 121.1, 120.0, 114.5, 83.8, 49.6, 45.1, 22.2, 21.3, 21.2. IR (KBr, neat) 3068, 2988, 2922, 1676, 1602, 1509, 1413, 1340, 1226, 1215, 1155, 1112, 1059, 1004, 980, 885, 817, 753, 671, 595, 572, 549, 529 cm⁻¹; HRMS (ESI) calcd. for C₂₅H₂₆N₃O₃S (M + H)⁺ 448.1689, found 448.1689.

(*S*)-3'-(4-Methoxyphenyl)-1-tosyl-1'*H*-spiro[pyrrolidine-2,4'-quinazolin]-2'(3'*H*)-one (8b):



White solid; R_f (Hexane:EtOAc, 3:7) 0.50; mp 220-222 °C. Yield 150 mg, 81%; ¹H NMR (400 MHz, CDCl₃/Methanol-d₄) δ 7.82 (dd, J = 8.8, 2.6 Hz, 1H), 7.18–7.12 (m, 2H), 7.05 (dd, J = 8.9, 3.0 Hz, 1H), 6.96 (d, J = 8.1 Hz, 2H), 6.92 (dd, J = 8.8, 3.0 Hz, 1H), 6.88 (d, J = 8.1 Hz, 2H), 6.80 (d, J = 8.0 Hz, 1H),


6.49-6.44 (m, 2H), 3.83 (s, 3H), 3.66 (t, J = 8.4 Hz, 1H), 3.15 (td, J = 9.5, 6.7 Hz, 1H), 2.69-2.53 (m, 2H), 2.31 (s, 3H), 1.57-1.49 (m, 1H), 0.90-0.78 (m, 1H). $^{13}C{^{1}H}$ NMR (125 MHz, CDCl₃/DMSO-d₆) δ 158.9, 151.6, 142.3, 137.1, 136.4, 132.6, 132.2, 130.7, 129.3, 128.9, 128.8, 126.6, 126.43, 126.38, 120.9, 119.8, 114.4, 114.3, 114.1, 83.8, 55.2, 49.6, 45.1, 22.1, 21.2. IR

(KBr, neat) 3065, 2928, 1675, 1603, 1511, 1413, 1339, 1249, 1157, 1113, 1008, 980, 836, 752, 672, 573, 548 cm⁻¹; HRMS (ESI) calcd. for $C_{25}H_{26}N_3O_4S$ (M + H)⁺ 464.1639, found 464.1639.

Experimental procedure and characterization data of compound 9:²

To an ice-cold solution of spiro-furan quinazolinone derivative **21** (113 mg, 0.4 mmol, 1.0 equiv.) in DCM (3.0 mL), N-Bromo succinimide (NBS) (85 mg, 0.48 mmol, 1.2 equiv.) was added portion wise over a period of 5 minutes. The reaction was stirred for 1.0 hour at room temperature, and the progress of the reaction was monitored by TLC. It was then treated with saturated $Na_2S_2O_3$ solution, and the organic layer was extracted with DCM (2 x 10 mL). The combined organic layers were further washed with brine, followed by drying over anhydrous Na_2SO_4 . The organic phase was concentrated in a rotary evaporator to give the crude product, which was then subjected to column chromatography over silica gel to provide the final product **9** as a white solid in 98% yield (141 mg).

(S)-6'-Bromo-3'-phenyl-4,5-dihydro-1'*H*,3*H*-spiro[furan-2,4'-quinazolin]-2'(3'*H*)-one (9):



White solid; R_f (Hexane:EtOAc, 1:1) 0.50; mp 194-196 °C. Yield 141 mg, 98%; ¹H NMR (400 MHz, CDCl₃) δ 9.28 (s, 1H), 7.47–7.44 (m, 1H), 7.43–7.38 (m, 4H), 7.37–7.37 (d, J = 1.6 Hz, 1H), 7.25 (dd, J = 8.5, 2.2 Hz, 1H), 6.55 (d, J = 8.5 Hz, 1H), 3.93–3.83 (m, 1H), 3.67–3.57 (m, 1H), 2.52–2.42 (m, 1H), 2.37–2.26 (m,

1H), 1.91–1.80 (m, 1H), 1.41–1.31 (m, 1H). ${}^{13}C{}^{1}H$ NMR (125 MHz, CDCl₃) δ 152.7, 137.7, 134.0, 132.2, 131.5, 129.0, 128.2, 127.9, 126.3, 116.4, 114.4, 96.8, 69.9, 39.7, 26.0. IR (KBr, neat) 3224, 2958, 1774, 1705, 1670, 1595, 1491, 1418, 1380, 1262, 1181, 1031, 817, 702, 641, 549, 510 cm⁻¹. HRMS (ESI) calcd. for C₁₇H₁₆BrN₂O₂ (M + H)⁺ 359.0390, found 359.0390.

References:

- S. Biswas, S. Shit, B. K. Behera, A. K. Sahu and A. K. Saikia, *Chem. Commun.*, 2023, 59, 14301-14304.
- B. Altenburg, M. Frings, J.-H. Schöbel, J. Goßen, K. Pannen, K. Vanderliek, G. Rossetti, S. Koschmieder, N. Chatain, C. Bolm, ACS Med. Chem. Lett., 2020, 11, 1928-1934.




Figure S1. ¹H spectrum of compound 1c (400 MHz, CDCl₃)




Figure S2. ¹³C spectrum of compound 1c (125 MHz, CDCl₃)




Figure S3. HRMS spectrum of 1c




Figure S4. ¹H spectrum of compound **1g** (400 MHz, CDCl₃/DMSO-d₆)




Figure S5. ¹³C spectrum of compound 1g (125 MHz, CDCl₃/DMSO-d₆)




Figure S6. HRMS spectrum of 1g

S30




Figure S7. ¹H spectrum of compound 1h (400 MHz, CDCl₃)




Figure S8. ¹³C spectrum of compound 1h (125 MHz, CDCl₃)




Figure S9. HRMS spectrum of 1h




Figure S10. ¹H spectrum of compound 1i (500 MHz, CDCl₃)




Figure S11. ¹³C spectrum of compound 1i (125 MHz, CDCl₃)




Figure S12. HRMS spectrum of 1i




Figure S13. ¹H spectrum of compound 1j (400 MHz, CDCl₃/DMSO-d₆)




Figure S14. ¹³C spectrum of compound 1j (125 MHz, CDCl₃/DMSO-d₆)




Figure S15. HRMS spectrum of 1j




Figure S16. ¹H spectrum of compound 1k (500 MHz, CDCl₃/DMSO-d₆)




Figure S17. ¹³C spectrum of compound 1k (125 MHz, CDCl₃/DMSO-d₆)




Figure S18. HRMS spectrum of 1k




Figure S19. ¹H spectrum of compound 1m (400 MHz, CDCl₃)




Figure S20. ¹³C spectrum of compound 1m (125 MHz, CDCl₃)




Figure S21. HRMS spectrum of 1m




Figure S22. ¹H spectrum of compound 1n (400 MHz, CDCl₃/DMSO-d₆)




Figure S23. ¹³C spectrum of compound 1n (125 MHz, CDCl₃/DMSO-d₆)




Figure S24. ¹⁹F spectrum of compound 1n (470 MHz, CDCl₃/DMSO-d₆/C₆F₆)




Figure S25. HRMS spectrum of 1n




Figure S26. ¹H spectrum of compound 10 (500 MHz, CDCl₃)




Figure S27. ¹³C spectrum of compound 10 (125 MHz, CDCl₃)




Figure S28. HRMS spectrum of 10




Figure S29. ¹H spectrum of compound 1p (400 MHz, CDCl₃)




Figure S30. ¹³C spectrum of compound 1p (125 MHz, CDCl₃)




Figure S31. HRMS spectrum of 1p




Figure S32. ¹H spectrum of compound 1q (500 MHz, CDCl₃/DMSO-d₆)




Figure S33. ¹³C spectrum of compound 1q (125 MHz, CDCl₃/DMSO-d₆)




Figure S34. HRMS spectrum of 1q




Figure S35. ¹H spectrum of compound **1r** (400 MHz, CDCl₃)




Figure S36. ¹³C spectrum of compound 1r (125 MHz, CDCl₃)




Figure S37. ¹⁹F spectrum of compound 1r (470 MHz, CDCl₃/C₆F₆)




Figure S38. HRMS spectrum of 1r




Figure S39. ¹H spectrum of compound 1w (400 MHz, CDCl₃)




Figure S40. ¹³C spectrum of compound 1w (125 MHz, CDCl₃)




Figure S41. HRMS spectrum of 1w




Figure S42. ¹H spectrum of compound 1x (500 MHz, CDCl₃)




Figure S43. ¹³C spectrum of compound 1x (125 MHz, CDCl₃)




Figure S44. HRMS spectrum of 1x




Figure S45. ¹H spectrum of compound 1y (500 MHz, CDCl₃)




Figure S46. ¹³C spectrum of compound 1y (125 MHz, CDCl₃)




Figure S47. HRMS spectrum of 1y




Figure S48. ¹H spectrum of compound 1aa (500 MHz, CDCl₃)




Figure S49. ¹³C spectrum of compound 1aa (125 MHz, CDCl₃)




Figure S50. HRMS spectrum of 1aa




Figure S51. ¹H spectrum of compound 1ab (500 MHz, CDCl₃)




Figure S52. ¹³C spectrum of compound 1ab (125 MHz, CDCl₃)




Figure S53. HRMS spectrum of 1ab




Figure S54. ¹H spectrum of compound 2a (500 MHz, CDCl₃)




Figure S55. ¹³C spectrum of compound 2a (125 MHz, CDCl₃)




Figure S56. HRMS spectrum of 2a




Figure S57. ¹H spectrum of compound 2b (400 MHz, CDCl₃)




Figure S58. ¹³C spectrum of compound 2b (125 MHz, CDCl₃)




Figure S59. HRMS spectrum of 2b




Figure S60. ¹H spectrum of compound 2c (400 MHz, CDCl₃)




Figure S61. ¹³C spectrum of compound 2c (125 MHz, CDCl₃)




Figure S62. HRMS spectrum of 2c




Figure S63. ¹H spectrum of compound 2d (400 MHz, CDCl₃)




Figure S64. ¹³C spectrum of compound 2d (125 MHz, CDCl₃)




Figure S65. HRMS spectrum of 2d

S89




Figure S66. ¹H spectrum of compound 2e (500 MHz, CDCl₃)




Figure S67. ¹³C spectrum of compound 2e (125 MHz, CDCl₃)




Figure S68. ¹⁹F spectrum of compound 2e (470 MHz, CDCl₃)




Figure S69. HRMS spectrum of 2e




Figure S70. ¹H spectrum of compound 2f (400 MHz, CDCl₃)




Figure S71. ¹³C spectrum of compound 2f (125 MHz, CDCl₃)




Figure S72. HRMS spectrum of 2f




Figure S73. ¹H spectrum of compound 2g (400 MHz, CDCl₃)




Figure S74. ¹³C spectrum of compound 2g (125 MHz, CDCl₃)




Figure S75. HRMS spectrum of 2g




Figure S76. ¹H spectrum of compound 2h (500 MHz, CDCl₃)




Figure S77. ¹³C spectrum of compound 2h (125 MHz, CDCl₃)




Figure S78. HRMS spectrum of 2h




Figure S79. ¹H spectrum of compound 2i (400 MHz, CDCl₃)




Figure S80. ¹³C spectrum of compound **2i** (125 MHz, CDCl₃)




Figure S81. HRMS spectrum of 2i




Figure S82. ¹H spectrum of compound 2j (400 MHz, CDCl₃)




Figure S83. ¹³C spectrum of compound 2j (125 MHz, CDCl₃)




Figure S84. HRMS spectrum of 2j

S108




Figure S85. ¹H spectrum of compound 2k (500 MHz, CDCl₃)





Figure S86. ¹³C spectrum of compound 2k (125 MHz, CDCl₃)

Figure S87. HRMS spectrum of 2k






Figure S88. ¹H spectrum of compound 2l (400 MHz, CDCl₃)




Figure S89. ¹³C spectrum of compound 2l (125 MHz, CDCl₃)




Figure S90. HRMS spectrum of 21




Figure S91. ¹H spectrum of compound 2m (500 MHz, CDCl₃)




Figure S92. ¹³C spectrum of compound 2m (125 MHz, CDCl₃)




Figure S93. HRMS spectrum of 2m




Figure S94. ¹H spectrum of compound 2n (400 MHz, CDCl₃/DMSO-d₆)




Figure S95. ¹³C spectrum of compound 2n (125 MHz, CDCl₃/DMSO-d₆)




Figure S96. ¹⁹F spectrum of compound 2n (470 MHz, CDCl₃/C₆F₆)




Figure S97. HRMS spectrum of 2n




Figure S98. ¹H spectrum of compound 20 (400 MHz, CDCl₃)




Figure S99. ¹³C spectrum of compound 20 (125 MHz, CDCl₃)




Figure S100. HRMS spectrum of 20




Figure S101. ¹H spectrum of compound 2p (400 MHz, CDCl₃)




Figure S102. ¹³C spectrum of compound 2p (125 MHz, CDCl₃)




Figure S103. HRMS spectrum of 2p




Figure S104. ¹H spectrum of compound 2q (400 MHz, CDCl₃/DMSO-d₆)




Figure S105. ¹³C spectrum of compound 2q (125 MHz, CDCl₃/DMSO-d₆)




Figure S106. HRMS spectrum of 2q




Figure S107. ¹H spectrum of compound 2r (400 MHz, CDCl₃)




Figure S108. ¹³C spectrum of compound 2r (125 MHz, CDCl₃)




Figure S109. ¹⁹F spectrum of compound 2r (470 MHz, CDCl₃/C₆F₆)




Figure S110. HRMS spectrum of 2r

S134




Figure S111. ¹H spectrum of compound 2s (500 MHz, CDCl₃)




Figure S112. ¹³C spectrum of compound 2s (125 MHz, CDCl₃)




Figure S113. HRMS spectrum of 2s

S137




Figure S114. ¹H spectrum of compound 2t (500 MHz, CDCl₃)




Figure S115. ¹³C spectrum of compound 2t (125 MHz, CDCl₃)




Figure S116. HRMS spectrum of 2t

-




Figure S117. ¹H spectrum of compound 2u (500 MHz, CDCl₃)




Figure S118. ¹³C spectrum of compound **2u** (125 MHz, CDCl₃)




Figure S119. HRMS spectrum of 2u

S143




Figure S120. ¹H spectrum of compound 2v (500 MHz, CDCl₃)




Figure S121. ¹³C spectrum of compound 2v (125 MHz, CDCl₃)




Figure S122. HRMS spectrum of 2v

S146




Figure S123. ¹H spectrum of compound 2w (400 MHz, CDCl₃)




Figure S124. ¹³C spectrum of compound 2w (125 MHz, CDCl₃)




Figure S125. HRMS spectrum of 2w

S149




Figure S126. ¹H spectrum of compound 2x (500 MHz, CDCl₃)




Figure S127. ¹³C spectrum of compound 2x (125 MHz, CDCl₃)




Figure S128. HRMS spectrum of 2x




Figure S129. ¹H spectrum of compound 2aa (400 MHz, CDCl₃)




Figure S130. ¹³C spectrum of compound 2aa (125 MHz, CDCl₃)




Figure S131. HRMS spectrum of 2aa




Figure S132. ¹H spectrum of compound 2ab (500 MHz, CDCl₃)




Figure S133. ¹³C spectrum of compound 2ab (125 MHz, CDCl₃)




Figure S134. HRMS spectrum of 2ab




Figure S135. ¹H spectrum of compound 5 (400 MHz, CDCl₃)




Figure S136. ¹³C spectrum of compound 5 (125 MHz, CDCl₃)




Figure S137. HRMS spectrum of 5




Figure S138. ¹H spectrum of compound 7a (500 MHz, CDCl₃)




Figure S139. ¹³C spectrum of compound 7a (125 MHz, CDCl₃)




Figure S140. HRMS spectrum of 7a




Figure S141. ¹H spectrum of compound 7b (400 MHz, CDCl₃)




Figure S142. ¹³C spectrum of compound 7b (125 MHz, CDCl₃)




Figure S143. HRMS spectrum of 7b




Figure S144. ¹H spectrum of compound 8a (500 MHz, CDCl₃/DMSO-d₆)




Figure S145. ¹³C spectrum of compound 8a (125 MHz, CDCl₃/DMSO-d₆)




Figure S146. HRMS spectrum of 8a




Figure S147. ¹H spectrum of compound 8b (400 MHz, CDCl₃/Methanol-d₄)




Figure S148. ¹³C spectrum of compound 8b (125 MHz, CDCl₃/DMSO-d₆)




Figure S149. HRMS spectrum of 8b




Figure S150. ¹H spectrum of compound 9 (400 MHz, CDCl₃)




Figure S151. ¹³C spectrum of compound 9 (125 MHz, CDCl₃)




Figure S152. HRMS spectrum of 9

Single crystal X-ray diffraction

Single crystal of compound **2a** was obtained by slow evaporation of hexane and ethyl acetate solution (4:1). Bruker APEX-II CCD diffractometer was used to collect the intensity data. The instrument is equipped with a fine focus 1.75 kW sealed tube Mo K α radiation ($\lambda = 0.71073$ Å) at 297(2) K. The data acquisition was done with the APEX4 software. APEX4 software was implemented for data integration and reduction. Multi-scan empirical absorption corrections were employed to the data using the program APEX4. Structures were solved by direct methods using SHELXL-2019 software and refined with full-matrix least-squares on F2 using SHELXL-2019/1.³ Structural illustrations have been drawn with ORTEP-3 for Windows.⁴ The detailed data collection and structure refinement are summarized in Table S1. CCDC-2334015 contained supplementary crystallographic data for this paper.

References:

- 3. G. M. Sheldrick, SHELXS-2014, Program for the crystal structure solution; University of Göttingen: Göttingen, Germany, 2014.
- 4. L. J. Farrugia, XRDIFF: simulation of X-ray diffraction patterns, *J. Appl. Crystallogr.*, 1997, **30**, 565.

Identification code	SB-210
CCDC:	2334015
Empirical formula	$C_{18}H_{18}N_2O_2$
Formula weight	294.34
Temperature	297(2) K
Wavelength	0.71073 Å
Crystal system	Monoclinic
Space group	P 21/n
Unit cell dimensions	$a = 12.5261(6) \text{ Å} \alpha = 90^{\circ}$
	$b = 7.3772(4) \text{ Å} \qquad \beta = 98.222(2)^{\circ}$
	$c = 16.8208(9) \text{ Å} \gamma = 90^{\circ}$
Volume	1538.39(14) Å ³
Z	4
Density (calculated)	1.271 mg/m ³
Absorption coefficient	0.084 mm ⁻¹
F(000)	624
Crystal size	$0.32\times0.31\times0.25\ mm^3$
Theta range for data collection	3.806 to 50.088°
Index ranges	$-14 \le h \le 14, -8 \le k \le 8, -20 \le l \le 20$
Reflections collected	32704
Independent reflections	2718 [$R_{int} = 0.0527$, $R_{sigma} = 0.0323$]
Completeness to theta = 25.02	99.9%
Refinement method	Full-matrix least-squares on F2
Data / restraints / parameters	2718/0/200
Goodness-of-fit on F2	1.189
Final R indices [I>2sigma(I)]	$\mathbf{R_1} = 0.0730$
	$\mathbf{wR}_2 = 0.1298$
R indices (all data)	$R_1 = 0.1141$
	$\mathbf{wR}_2 = 0.1506$
Extinction coefficient	n/a
Largest diff. peak and hole	0.145 and -0.171 e.Å ⁻³

 Table S1. Crystal parameters of compound 2a




Figure S153. ORTEP diagram of compound 2a with thermal ellipsoid of 30% probability.